Hydropyrido[1,2-a]pyrazine compounds for the treatment of autoimmune diseases

Abstract

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, which act as antagonists of Toll-like receptors TLR7, TLR8 and / or TLR9 and are therefore useful in the treatment of systemic lupus erythematosus (SLE) and lupus nephritis. TIFF2023505159000083.tif54165

Description

[Technical field]

[0001] The present invention relates to organic compounds useful for therapy and / or prophylaxis in mammals, in particular antagonists of TLR7 and / or TLR8 and / or TLR9 useful for treating systemic lupus erythematosus or lupus nephritis. [Background technology]

[0002] Autoimmune connective tissue diseases (CTDs) include the prototypic autoimmune syndromes such as systemic lupus erythematosus (SLE), primary Sjögren's syndrome (pSjS), mixed connective tissue disease (MCTD), dermatomyositis / polymyositis (DM / PM), rheumatoid arthritis (RA), and systemic sclerosis (SSc). With the exception of RA, there is no truly effective and safe therapy available for patients. SLE is the prototypic CTD with a prevalence of 20-150 cases per 100,000, resulting in widespread inflammation and tissue damage in different organs, from the usually observed symptoms in the skin and joints to renal, lung, or cardiac failure. Traditionally, SLE has been treated with nonspecific anti-inflammatory or immunosuppressive drugs. However, the long-term use of immunosuppressive drugs, e.g., corticosteroids, is only partially effective and is associated with undesirable toxicities and side effects. Belimumab is the only FDA-approved drug for lupus in the last 50 years, but its efficacy is weak and delayed, and is only seen in a small proportion of SLE patients (Navarra, SV et al Lancet 2011,377,721).Other biologics, such as anti-CD20 mAb, mAbs against certain cytokines or soluble receptors of said cytokines, have failed in most clinical trials.Therefore, new therapies are needed that provide sustained improvement in a larger proportion of the patient population and are safer for long-term use in many autoimmune and autoinflammatory diseases.

[0003] Toll-like receptors (TLRs) are an important family of pattern recognition receptors (PRRs) that can initiate a wide range of immune responses in a wide variety of immune cells. As natural host defense sensors, endosomal TLR7, 8 and 9 recognize nucleic acids derived from viruses, bacteria, and specifically, TLR7 / 8 and TLR9 recognize single-stranded RNA (ssRNA) and single-stranded CpG-DNA, respectively. However, aberrant nucleic acid detection of TLR7, 8 and 9 is considered as a critical node in a wide range of autoimmune and autoinflammatory diseases (Krieg, AM et al. Immunol. Rev. 2007, 220, 251. Jimenez-Dalmaroni, MJ et al Autoimmun Rev. 2016, 15, 1. Chen, JQ, et al. Clinical Reviews in Allergy & Immunology 2016, 50, 1). Anti-RNA and anti-DNA antibodies are well-established SLE diagnostic markers, and these antibodies can deliver both self-RNA and self-DNA to endosomes. Self-RNA complexes can be recognized by TLR7 and TLR8, whereas self-DNA complexes can trigger the activation of TLR9. Indeed, defects in the clearance of self-RNA and self-DNA from blood and / or tissues are evident in SLE (systemic lupus erythematosus) patients. TLR7 and TLR9 have been reported to be upregulated in SLE tissues and correlated with the chronicity and activity of lupus nephritis, respectively. In B cells of SLE patients, TLR7 expression correlates with anti-RNP antibody production, whereas TLR9 expression correlates with IL-6 levels and anti-double-stranded DNA antibody levels. Consistently, in lupus mouse models, TLR7 is required for anti-RNA antibodies, and TLR9 is required for anti-nucleosome antibodies. Meanwhile, overexpression of TLR7 or human TLR8 in mice promotes autoimmunity and autoinflammation. Moreover, TLR8 activation specifically contributes to mDC / macrophage inflammatory cytokine secretion, neutrophil nematosis, induction of Th17 cells, and suppression of Treg cells.In addition to the described role of TLR9 in promoting B cell autoantibody production, activation of TLR9 by self-DNA in pDCs also leads to the induction of type I IFN and other inflammatory cytokines. Considering these roles of TLR9 in both pDCs and B cells, both as an important contributor to the pathogenesis of autoimmune diseases and as the widespread presence of self-DNA complexes that can easily activate TLR9 in many patients suffering from autoimmune diseases, further blocking the self-DNA-mediated TLR9 pathway in addition to inhibiting the TLR7 and TLR8 pathways may have additional benefits. Taken together, the TLR7, 8, and 9 pathways represent new therapeutic targets for the treatment of autoimmune and autoinflammatory diseases for which there are no effective steroid-free and non-cytotoxic oral drugs, and inhibiting all of these pathways from the most upstream may provide satisfactory therapeutic effects. Therefore, the present inventors have invented oral compounds that target and suppress TLR7, TLR8, and TLR9 for the treatment of autoimmune and autoinflammatory diseases. Summary of the Invention

[0004] The present invention relates to a compound of formula (I): [ka] (In the formula, R 1 teeth, [ka] where R 4 is C 1-6 Alkyl, C 1-6 Alkoxy, HaloC 1-6 R is alkyl, halogen, nitro or cyano; 4a is C 1-6 Alkyl or C 3-7 Cycloalkyl; R 5 , R 5a and R 5b are independently selected from H and deuterium; R 6is H or a halogen; R 2 is C 1-6 is alkyl; R 3 is ((amino (C 1-6 alkoxy)pyrrolidinyl)phenyl)azetidinyl, (amino(C 1-6 alkoxy)pyrrolidinyl)pyridinyl, (amino(C 1-6 (Alkoxy)pyrrolidinyl)pyridinyloxy, (amino-1,4-oxazepanyl)pyridinyl, (aminoazetidinyl)pyridinyl, (morpholinyl C 1-6 Alkyl)phenyl, (morpholinyl C 1-6 (Alkyl)phenylamino, (piperazinylphenyl)azetidinyl, (piperazinylphenyl)C 1-6 alkylamino, aminohalopyrrolidinyl, morpholinylphenyl, morpholinylphenylamino, piperazinylphenyl, piperazinylpyridinyl, piperazinylpyridinyloxy, piperazinylpyrimidinyloxy or pyridinylpiperazinyl). or a pharma- ceutically acceptable salt thereof.

[0005] Another object of the present invention relates to a novel compound of formula (I) and its preparation, a medicament based on the compound according to the present invention and its preparation, the use of the compound of formula (I) as an antagonist of TLR7 and / or an antagonist of TLR8 and / or an antagonist of TLR9, and its use for the treatment or prevention of systemic lupus erythematosus or lupus nephritis. The compound of formula (I) shows excellent antagonistic activity of TLR7 and TLR8 and TLR9. In addition, the compound of formula (I) also shows good cytotoxicity, phototoxicity, solubility, hPBMC, human microsome stability and SDPK profile, and low CYP inhibition. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0006] definition "C 1-6The term "alkyl" refers to saturated straight or branched chain alkyl groups containing 1 to 6, especially 1 to 4, carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, etc. 1-6 The "alkyl" groups are methyl, ethyl, and n-propyl.

[0007] The terms "halogen" and "halo" are used interchangeably herein and mean fluoro, chloro, bromo, or iodo.

[0008] The term "aryl" refers to an aromatic hydrocarbon monocyclic or bicyclic ring system of 5 to 12 ring atoms. Examples of aryl include, but are not limited to, phenyl and naphthyl. Aryl includes, but is not limited to, C 1-6 Alkyl;3,4,4a,5,7,7a-Hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl;1,4-diazepanyl;C 1-6 Alkyl-substituted 2,6-diazaspiro[3.3]heptanyl; 5-oxa-2,8-diazaspiro[3.5]nonanyl; amino-1,4-oxazepanyl; amino and C 1-6 Azetidinyl substituted with one or two substituents independently selected from alkyl; unsubstituted or C 1-6 Alkyl-substituted piperazinyl; and amino, C 1-6 It may be further substituted by substituents including pyrrolidinyl substituted with one or two substituents independently selected from alkoxy and halogen.

[0009] The term "heteroaryl" refers to an aromatic heterocyclic monocyclic or bicyclic ring system of 5 to 12 ring atoms containing 1, 2, 3, or 4 heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon. Examples of heteroaryl include, but are not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl. Heteroaryl includes, but is not limited to, C 1-6 Alkyl;3,4,4a,5,7,7a-Hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl;1,4-diazepanyl;C 1-6 Alkyl-substituted 2,6-diazaspiro[3.3]heptanyl; 5-oxa-2,8-diazaspiro[3.5]nonanyl; amino-1,4-oxazepanyl; amino and C 1-6 Azetidinyl substituted with one or two substituents independently selected from alkyl; unsubstituted or C 1-6 Alkyl-substituted piperazinyl; and amino, C 1-6 It may be further substituted by substituents including pyrrolidinyl substituted with one or two substituents independently selected from alkoxy and halogen.

[0010] The term "heterocyclyl" or "heterocyclic" denotes a monovalent saturated or partially unsaturated monocyclic or bicyclic ring system of 3 to 12 ring atoms containing 1 to 5 ring heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon. In certain embodiments, a heterocyclyl is a monovalent saturated monocyclic ring system of 4-7 ring atoms containing 1, 2, or 3 ring heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon. Examples of monocyclic saturated heterocyclyls are aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, or oxazepanyl. Examples of bicyclic saturated heterocycles are azabicyclo[3.2.1]octyl, quinuclidinyl, oxazabicyclo[3.2.1]octanyl, azabicyclo[3.3.1]nonanyl, oxazabicyclo[3.3.1]nonanyl, azabicyclo[3.1.0]hexanyl, oxodiazaspiro[3.4]octanyl, acetyloxodiazaspiro[3.4]octanyl, thiazabicyclo[3.3.1]nonanyl, oxoazaspiro[2.4]heptanyl, oxoazaspiro[3.4]octanyl, oxoazabicyclo[3.1.0]hexanyl and dioxotetrahydropyrrolo[1,2-a]pyrazinyl.Examples of bicyclic heterocyclyls include 1,2,3,4-tetrahydroisoquinolinyl; 5,6,7,8-tetrahydro-1,6-naphthyridinyl; 5,6,7,8-tetrahydro-1,7-naphthyridinyl; 5,6,7,8-tetrahydro-2,6-naphthyridinyl; 5,6,7,8-tetrahydro-2,7-naphthyridinyl; isoindolinyl; 3,4-dihydro-1H-2,6-naphthyridinyl; 7,8-dihydro-5H-1,6-naphthyridinyl; Examples of heterocyclyls include, but are not limited to, 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridinyl; 6,7-dihydro-5H-pyrrolo[3,4-b]pyridinyl; 2,9-diazaspiro[5.5]undecanyl; 3,8-diazabicyclo[3.2.1]octanyl; 7,8-dihydro-5H-pyrido[3,4-b]pyrazinyl; 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidinyl and 3,4-dihydro-1H-isoquinolinyl. Monocyclic or bicyclic heterocyclyls include, but are not limited to, amino, hydroxy, halogen, C. 1-6 Alkyl, C 1-6 It may be further substituted with alkoxy or heterocyclyl.

[0011] The term "heterocyclylheteroaryl" refers to heterocyclyl-heteroaryl-.

[0012] "Heterocyclyl C 1-6 The term "alkylaryl" refers to heterocyclyl-C 1-6 Alkyl-aryl-.

[0013] The term "pharmaceutically acceptable salt" means a salt that is not biologically or otherwise undesirable. Pharmaceutically acceptable salts include both acid addition salts and base addition salts.

[0014] The term "pharmaceutically acceptable acid addition salt" refers to pharmaceutically acceptable salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and the like, and organic acids selected from the aliphatic, alicyclic, aromatic, aryl-containing aliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids, such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid.

[0015] The term "pharmaceutically acceptable base addition salt" refers to a pharmaceutically acceptable salt formed with an organic or inorganic base. Examples of acceptable inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperidine, piperidine, N-ethylpiperidine, and polyamine resins.

[0016] The term "pharmaceutical active metabolite" refers to a pharmacologically active product produced through metabolism in the body of a particular compound or its salt. After entering the body, most drugs become substrates for chemical reactions that can change the physical properties and biological effects of the substrate. These metabolic transformations usually affect the polarity of the compounds of the present invention and change the way the drug is distributed in and excreted from the body. However, in some cases, drug metabolism is required for therapeutic effect.

[0017] The term "therapeutically effective amount" refers to an amount of a compound or molecule of the invention that, when administered to a subject, (i) treats or prevents a particular disease, condition or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of a particular disease, condition or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition or disorder described herein. The therapeutically effective amount will vary depending on the compound, the disease state being treated, the severity of the disease being treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending physician or veterinarian, and other factors.

[0018] The term "pharmaceutical composition" refers to a combination or solution containing a therapeutically effective amount of an active pharmaceutical ingredient together with a pharma- ceutically acceptable excipient to be administered to a mammal, e.g., a human, in need of the pharmaceutical composition.

[0019] TLR7 and / or TLR8 and / or TLR9 antagonists The present invention relates to a method for producing a compound represented by the formula (I): [ka] (In the formula, R 1 teeth, [ka] where R 4 is C1-6 Alkyl, C 1-6 Alkoxy, HaloC 1-6 R is alkyl, halogen, nitro or cyano; 4a is C 1-6 Alkyl or C 3-7 Cycloalkyl; R 5 , R 5a and R 5b are independently selected from H and deuterium; R 6 is H or a halogen; R 2 is C 1-6 is alkyl; R 3 is ((amino (C 1-6 alkoxy)pyrrolidinyl)phenyl)azetidinyl, (amino(C 1-6 alkoxy)pyrrolidinyl)pyridinyl, (amino(C 1-6 (Alkoxy)pyrrolidinyl)pyridinyloxy, (amino-1,4-oxazepanyl)pyridinyl, (aminoazetidinyl)pyridinyl, (morpholinyl C 1-6 Alkyl)phenyl, (morpholinyl C 1-6 (Alkyl)phenylamino, (piperazinylphenyl)azetidinyl, (piperazinylphenyl)C 1-6 alkylamino, aminohalopyrrolidinyl, morpholinylphenyl, morpholinylphenylamino, piperazinylphenyl, piperazinylpyridinyl, piperazinylpyridinyloxy, piperazinylpyrimidinyloxy or pyridinylpiperazinyl). or a pharma- ceutically acceptable salt thereof.

[0020] A further embodiment of the present invention is a compound of formula (I) as defined in (ii)(i), or a pharma- ceutically acceptable salt thereof, wherein R 1 teeth, [ka] where R 4 is cyano; R 5 is H or deuterium.

[0021] A further embodiment of the present invention is a compound of formula (I) as defined in (iii)(i) or (ii), or a pharma- ceutically acceptable salt thereof, wherein R 3 ((3-amino-4-methoxy-pyrrolidin-1-yl)phenyl)azetidin-1-yl;(3-amino-4-methoxy-pyrrolidin-1-yl)-3-pyridinyl;(3-amino-4-methoxy-pyrrolidin-1-yl)-3-pyridinyloxy;(3-aminoazetidin-1-yl)-3-pyridinyl;(4-morpholin-2-ylmethyl)phenyl;(4-morpholin-2-ylmethyl)phenylamino;(4-piperazin-1-ylphenyl)azetidin-1-yl;(4-piperazin-1-ylphenyl)methylamino;(6-aminoazetidin-1-yl)azetidin-1-yl;(4-piperazin-1-ylphenyl)methylamino;(6-aminoazetidin-1-yl)azetidin-1-yl;(4-piperazin-1-ylphenyl)methylamino;(6-aminoazetidin-1-yl)azetidin-1-yl;(4-aminoazetidin-1-yl)azetidin-1-yl;(4-aminoazetidin-1-yl)azetidin-1-yl;(4-aminoazetidin-1-yl)azetidin-1-yl;(4-aminoazetidin-1-yl)methylamino;(6 ...methylamino;(6-aminoazetidin-1-yl)azetidin-1-yl;(4-aminoazetidin-1-yl)azetidin-1-yl;(4-aminoazetidin- no-1,4-oxazepan-4-yl)-3-pyridinyl; 2-piperazin-1-ylpyrimidin-5-yloxy; 3-amino-4-fluoro-pyrrolidin-1-yl; 4-morpholin-2-ylphenyl; 4-morpholin-2-ylphenylamino; 4-piperazin-1-ylphenyl; 4-pyridinylpiperazin-1-yl; 5-piperazin-1-yl-2-pyridinyloxy; 5-piperazin-1-yl-3-pyridinyloxy; 6-piperazin-1-yl-3-pyridinyl or 6-piperazin-1-yl-3-pyridinyloxy.

[0022] A further embodiment of the present invention is a compound of formula (I) according to any one of (iv)(i) to (iii), or a pharma- ceutically acceptable salt thereof, wherein R 2 is methyl.

[0023] A further embodiment of the present invention is a compound of formula (I) according to any one of (v)(i) to (iv), wherein R 3 (morpholinyl C 1-6 (alkyl)phenylamino, (piperazinylphenyl)azetidinyl, morpholinylphenyl, morpholinylphenylamino, piperazinylpyridinyloxy or piperazinylpyrimidinyloxy.

[0024] A further embodiment of the present invention is a compound of formula (I) according to any one of (i) to (v), or a pharma- ceutically acceptable salt thereof, wherein R 3 is (4-morpholin-2-ylmethyl)phenylamino, (4-piperazin-1-ylphenyl)azetidin-1-yl, 4-morpholin-2-ylphenyl, 4-morpholin-2-ylphenylamino, 6-piperazin-1-yl-3-pyridinyloxy or 2-piperazin-1-ylpyrimidin-5-yloxy.

[0025] A further embodiment of the present invention is a compound of formula (I) according to any one of (i) to (vi), or a pharma- ceutically acceptable salt thereof, wherein: R 1 teeth, [ka] where R 4 is cyano; R 5 is H or deuterium; R 2 is C 1-6 is alkyl; R 3 (morpholinyl C 1-6 (alkyl)phenylamino, (piperazinylphenyl)azetidinyl, morpholinylphenyl, morpholinylphenylamino, piperazinylpyridinyloxy or piperazinylpyrimidinyloxy.

[0026] A further embodiment of the present invention is a compound of formula (I) according to any one of (i) to (vii), or a pharma- ceutically acceptable salt thereof, wherein: R 1 teeth, [ka] where R 4 is cyano; R 5 is H or deuterium; R2 is methyl, R 3 is (4-morpholin-2-ylmethyl)phenylamino, (4-piperazin-1-ylphenyl)azetidin-1-yl, 4-morpholin-2-ylphenyl, 4-morpholin-2-ylphenylamino, 6-piperazin-1-yl-3-pyridinyloxy or 2-piperazin-1-ylpyrimidin-5-yloxy.

[0027] Another embodiment of the present invention is a method for producing a composition comprising the steps of: 5-[(4R,8R,9aS)-4-methyl-8-[(4-piperazin-1-ylphenyl)methylamino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-[(4-piperazin-1-ylphenyl)methylamino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R)-4-methyl-8-(6-piperazin-1-yl-3-pyridyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R)-4-methyl-8-(4-piperazin-1-ylphenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-(6-piperazin-1-yl-3-pyridyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-[(3S,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-(3-aminoazetidin-1-yl)-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-[3-(4-piperazin-1-ylphenyl)azetidin-1-yl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-[(5-piperazin-1-yl-2-pyridyl)oxy]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-[(3S,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aR)-4-methyl-8-(6-piperazin-1-yl-3-pyridyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-[(6-piperazin-1-yl-3-pyridyl)oxy]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-(2-piperazin-1-ylpyrimidin-5-yl)oxy-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-[(3R,4S)-3-amino-4-fluoro-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-[4-[(2S)-morpholin-2-yl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-[4-[[(2R)-morpholin-2-yl]methyl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-Methyl-8-[4-[[(2R)-morpholin-2-yl]methyl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile 5-[(4R,8R,9aS)-4-methyl-8-[4-[[(2R)-morpholin-2-yl]methyl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-[(6S)-6-amino-1,4-oxazepan-4-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-(4-morpholin-2-ylphenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-[4-[(2R)-morpholin-2-yl]phenyl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-[4-[[(2R)-morpholin-2-yl]methyl]phenyl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-[4-(morpholin-2-ylmethyl)phenyl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-8-[[6-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]oxy]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-[(5-piperazin-1-yl-3-pyridyl)oxy]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[3-[4-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]phenyl]azetidin-1-yl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[3-[4-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]phenyl]azetidin-1-yl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-[4-[[(2S)-morpholin-2-yl]methyl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[3-[4-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]phenyl]azetidin-1-yl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]]-2-deuterio-quinoline-8-carbonitrile; and 5-[(4R,8R,9aS)-4-methyl-8-[4-(4-pyridyl)piperazin-1-yl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile; or a pharma- ceutically acceptable salt thereof.

[0028] synthesis The compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds and their starting materials are provided in the following schemes and in the examples. All substituents, particularly R 1 and R 2are as defined above unless otherwise indicated. Further, unless expressly stated otherwise, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to one of ordinary skill in the art of organic chemistry.

[0029] General synthetic routes for preparing compounds of formula (I), and (VI), and (X), and (XV), and (XIX) are set out below.

[0030] Scheme 1 [ka] (wherein X is a halogen; R 7 is H;R 8 Heterocyclylheteroaryl, HeterocyclylC 1-6 Alkylheteroaryl, heterocyclylheteroaryl C 1-6 Alkyl, Heterocyclyl C 1-6 Alkylaryl, heterocyclylaryl C 1-6 alkyl; or R 7 and R 8 form a heterocyclyl together with the nitrogen to which they are attached.)

[0031] The synthesis of the above compounds started from the reaction of bicyclic amines, i.e. compounds of formula (III), with halides (II) via Buchwald-Hartwig amination reaction in the presence of a catalyst such as Ruphos Pd-G2 and a base such as Cs2CO3 to provide compounds of formula (IV) (see Acc. Chem. Res. 1998, 31, 805-818; Chem. Rev. 2016, 116, 12564-12649; Topics in Current Chemistry, 2002, 219, 131-209; and references cited therein). Alternatively, compounds of formula IV can also be obtained via nucleophilic substitution between halides (II) and compounds of formula (III) in the presence of a base such as DIPEA, NaHCO3, and K2CO3. Compounds of formula (VI) and (VIII) can be obtained from compounds of formula (IV) via Borsch reductive amination with amines of compounds of formula (V) and (VII), respectively, in the presence of a reducing agent such as NaCNBH3. Coupling of compounds of formula (VIII) with amines (V) can be achieved under Buchwald-Hartwig amination conditions (see: Acc. Chem. Res. 1998, 31, 805-818; Chem. Rev. 2016, 116, 12564-12649; Topics in Current Chemistry, 2002, 219, 131-209; and references cited therein) using catalysts such as tBuXPhos Pd G3, RuPhos Pd G2, BrettPhos Pd G3, XPhos Pd G3, Pd2(dba)3 / BINAP and Pd2(dba)3 / XantPhos and bases such as Cs2CO3 or t-BuONa to provide compounds of formula (X).

[0032] Scheme 2 [ka] (wherein X is a halogen; R 7 is H;R 8 Heterocyclylheteroaryl, HeterocyclylC 1-6Alkylheteroaryl, heterocyclylheteroaryl C 1-6 Alkyl, Heterocyclyl C 1-6 Alkylaryl, heterocyclylaryl C 1-6 alkyl; or R 7 and R 8 together with the nitrogen to which they are attached form a heterocyclyl; W is heteroaryl or aryl.

[0033] The compound of formula (IV) can be reacted with tosylhydrazine (XI) to obtain the compound of formula (XII). The compound of formula (XIV) can be obtained via reductive coupling of the compound of formula (XII) with the boronic acid of formula (XIII) in the presence of a base such as Cs2CO3, DIPEA, NaHCO3 and K2CO3 (see: Chem. Eur. J. 2016, 22, 6253-6257; J. Org.Chem. 2014, 79, 328-338). Coupling of amines (V) and compounds of (XIV) can be achieved under Buchwald-Hartwig amination conditions (see: Acc. Chem. Res. 1998, 31, 805-818; Chem. Rev. 2016, 116, 12564-12649; Topics in Current Chemistry, 2002, 219, 131-209; and references cited therein) using catalysts such as tBuXPhos Pd G3, RuPhos Pd G2, BrettPhos Pd G3, XPhos Pd G3, Pd2(dba)3 / BINAP and Pd2(dba)3 / XantPhos and bases such as Cs2CO3 or t-BuONa to provide compounds of formula (XV).

[0034] A synthetic route for preparing compounds of formula XIX is shown in Scheme 3.

[0035] Scheme 3 [ka] (wherein X is a halogen; R 7 is H;R8 Heterocyclylheteroaryl, HeterocyclylC 1-6 Alkylheteroaryl, heterocyclylheteroaryl C 1-6 Alkyl, Heterocyclyl C 1-6 Alkylaryl, heterocyclylaryl C 1-6 alkyl; or R 7 and R 8 together with the nitrogen to which they are attached form a heterocyclyl; W is heteroaryl or aryl.

[0036] Reduction of the compound of formula (IV) in the presence of a reducing agent such as NaBH4 gives the compound of formula (XVI), which can be transformed to the compound of formula (XVIII) via Mitsunobu reaction in the presence of diethyl azodicarboxylate (DEAD) or diisopropyl azodicarboxylate (DIAD) and Ph3P. Coupling of amines (V) and compounds (XVIII) can be achieved under Buchwald-Hartwig amination conditions (see: Acc. Chem. Res. 1998, 31, 805-818; Chem. Rev. 2016, 116, 12564-12649; Topics in Current Chemistry, 2002, 219, 131-209; and references cited therein) using catalysts such as tBuXPhos Pd G3, RuPhos Pd G2, BrettPhos Pd G3, XPhos Pd G3, Pd2(dba)3 / BINAP and Pd2(dba)3 / XantPhos and bases such as Cs2CO3 or t-BuONa to provide compounds of formula (XIX).

[0037] The compounds of the invention may be obtained as mixtures of diastereomers or enantiomers, which may be separated by methods well known in the art, for example (chiral) HPLC or SFC.

[0038] The present invention also relates to a process for preparing a compound of formula (I), the process comprising the steps of: a) a compound of formula (VIII), [ka] and amine (V), [ka] Buchwald-Hartwig amination reaction between; b) amines (V), [ka] Compounds of formula (IV) using [ka] reductive amination of; c) a compound of formula (XIV), [ka] and amine (V), [ka] Buchwald-Hartwig amination reaction between; d) a compound of formula (XVIII), [ka] and amine (V), [ka] Buchwald-Hartwig amination reaction between; (wherein X is a halogen; R 7 is H;R 8 Heterocyclylheteroaryl, HeterocyclylC 1-6 Alkylheteroaryl, heterocyclylheteroaryl C1-6 Alkyl, Heterocyclyl C 1-6 Alkylaryl, heterocyclylaryl C 1-6 alkyl; or R 7 and R 8 together with the nitrogen to which they are attached form a heterocyclyl; W is heteroaryl or aryl. Contains one of the following:

[0039] The compounds of formula (I) when prepared by the above process are also an object of the present invention.

[0040] Indications and Treatment Methods The present invention provides compounds that can be used as antagonists of TLR7 and / or TLR8 and / or TLR9, which inhibit the activation of pathways via TLR7 and / or TLR8 and / or TLR9, and the respective downstream biological events, including but not limited to the innate and adaptive immune responses mediated via the production of all kinds of cytokines and all forms of autoantibodies.Thus, the compounds of the present invention are useful for blocking such receptor(s) in all kinds of cells that express TLR7 and / or TLR8 and / or TLR9, including but not limited to plasmacytoid dendritic cells, B cells, T cells, macrophages, monocytes, neutrophils, keratinocytes, epithelial cells.As such, the compounds can be used as therapeutic or prophylactic agents for systemic lupus erythematosus and lupus nephritis.

[0041] The present invention provides methods for the treatment or prevention of systemic lupus erythematosus and lupus nephritis in a patient in need thereof.

[0042] Another embodiment includes a method of treating or preventing systemic lupus erythematosus and lupus nephritis in a mammal in need of such treatment, comprising administering to said mammal a therapeutically effective amount of a compound of formula (I), a stereoisomer, tautomer, prodrug or a pharma- ceutically acceptable salt thereof. EXAMPLES

[0043] The present invention will be more fully understood by reference to the following examples, which should not, however, be construed as limiting the scope of the invention.

[0044] Abbreviation The present invention will be more fully understood by reference to the following examples, which should not, however, be construed as limiting the scope of the invention. Abbreviations used herein are as follows: [Table 1]

[0045] General experimental conditions Intermediates and final compounds were purified by flash chromatography using one of the following instruments: i) Biotage SP1 system and Quad12 / 25 Cartridge module; ii) ISCO Combi-Flash Chromatography machine. Silica gel brand and pore size: i) KP-SIL 60 Å, particle size: 40-60 μm; ii) CAS registration number: Silica gel: 63231-67-4, particle size: 47-60 micron silica gel; iii) ZCX from Qingdao Haiyang Chemical Co.,Ltd, pore: 200-300 or 300-400.

[0046] Intermediates and final compounds were analyzed using XBridge TM Prep-C18 (5 μm, OBD TM 30×100mm) column, SunFire TM Prep-C18 (5 μm, OBDTM Purification was by preparative HPLC on reversed-phase columns using a Phenomenex Synergi-C18 (10 μm, 25×150 mm) or Phenomenex Gemini-C18 (10 μm, 25×150 mm) column, a Waters AutoP purification system (sample manager 2767, pump 2525, detectors: Micromass ZQ and UV2487, solvent system: acetonitrile and 0.1% ammonium hydroxide in water; acetonitrile and 0.1% FA in water or acetonitrile and 0.1% TFA in water), or a Gilson-281 purification system (pump 322, detector: UV 156, solvent system: acetonitrile and 0.05% ammonium hydroxide in water; acetonitrile and 0.225% FA in water; acetonitrile and 0.05% HCl in water; acetonitrile and 0.075% TFA in water; or acetonitrile and water).

[0047] For SFC chiral separations, intermediates were separated by chiral columns (Daicel chiralpak IC, 5 μm, 30 × 250 mm), AS (10 μm, 30 × 250 mm) or AD (10 μm, 30 × 250 mm) using a Mettler Toledo Mutigram III system SFC, Waters 80Q preparative SFC or Thar80 preparative SFC, solvent system: CO2 and IPA (0.5% TEA in IPA) or CO2 and MeOH (0.1% NH3·H2O in MeOH), back pressure 100 bar, UV detection at 254 or 220 nm.

[0048] LC / MS spectra of the compounds were analyzed by LC / MS (Waters TM The LC / MS conditions were as follows (run time 3 or 1.5 min): Acidic conditions I: A: 0.1% TFA in HO, B: 0.1% TFA in acetonitrile Acidic conditions II: A: 0.0375% TFA in HO, B: 0.01875% TFA in acetonitrile Basic condition I: A: 0.1% NH3·H2O in H2O, B: acetonitrile; Basic condition II: A: 0.025% NH3·H2O in H2O, B: acetonitrile, Neutral conditions: A: H2O, B: Acetonitrile Mass Spectra (MS): Generally, only ions representing parent masses are reported, and unless otherwise stated, the mass ions quoted are the positive mass ions (M−H) + It is.

[0049] NMR spectra were obtained using a Bruker Avance 400 MHz.

[0050] Microwave-assisted reactions were carried out in a Biotage Initiator Sixty microwave synthesizer. All reactions involving air-sensitive reagents were carried out under an argon or nitrogen atmosphere. Reagents were used as received from commercial suppliers without further purification unless otherwise noted.

[0051] Preparation Examples The following examples are intended to illustrate the meaning of the invention, but in no way represent a limitation within the meaning of the invention.

[0052] Intermediate A1 5-Fluoroquinoline-8-carbonitrile [ka]

[0053] The title compound was synthesized according to the following scheme. [ka]

[0054] Step 1: Preparation of 8-bromo-5-fluoro-quinoline (compound A1.2) In a 100 mL pear-shaped flask, 2-bromo-5-fluoroaniline (compound A1.1, 2.0 g, 10.5 mmol), propane-1,2,3-triol (969 mg, 10.5 mmol) and sodium 3-nitrobenzenesulfonate (2.4 g, 10.5 mmol) were combined with 70% H2SO4 (20 mL) to give a dark brown solution. The solution was heated to 150 °C and stirred for 3 h. After cooling to room temperature, the reaction mixture was poured into ice water and neutralized with sodium hydroxide solution. The resulting mixture was filtered. The filter cake was dissolved in EtOAc and filtered. The filtrate was concentrated in vacuo. The crude material was purified by flash chromatography (silica gel, 40 g, 0% to 30% EtOAc in PE) to give compound A1.2 (2.0 g, 84% yield). MS: calculated 226 and 228 (MH + ), measured values ​​of 226 and 228 (MH + ).

[0055] Step 2: Preparation of 5-fluoroquinoline-8-carbonitrile (Intermediate A1) To a solution of 8-bromo-5-fluoroquinoline (compound A1.2, 4.9 g, 21.7 mmol) in DMF (30 mL) was added dicyanozinc (5.0 g, 43.4 mmol) and RuPhos Pd G2 (CAS: 1375325-68-0, Sigma-Aldrich, Cat#: 753246, 842 mg, 1.1 mmol). The reaction mixture was stirred at 100 °C for 3 h and then cooled to room temperature. The reaction mixture was filtered and the filtrate was diluted with water (50 mL) and then extracted three times with EA (80 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 40 g, 0% to 70% EtOAc in PE) to give intermediate A1 (3.0 g, 80% yield). MS: calcd. 173 (MH + ), measured value 173(MH + ). 1H NMR(400MHz, methanol-d4)δ 9.11(dd,J=4.28,1.71Hz,1H), 8.64(dd,J=8.56,1.71Hz,1H), 8.29(dd,J=8.1 9,5.62Hz,1H), 7.76(dd,J=8.56,4.28Hz,1H), 7.49(dd,J=9.35,8.25Hz,1H).

[0056] Intermediate A2 2-Deuterio-5-fluoro-quinoline-8-carbonitrile [ka]

[0057] The title compound was synthesized according to the following scheme. [ka]

[0058] Step 1: Preparation of N-(2-bromo-5-fluoro-phenyl)-3,3-dimethoxy-propanamide (Compound A2.2) To a solution of 2-bromo-5-fluoroaniline (compound A2.1, 50 g, 263 mmol) and methyl 3,3-dimethoxypropionate (45 mL, 316 mmol) in THF (150 mL) was added NaHMDS in THF (394 mL, 394 mmol) dropwise at 0° C. The mixture was stirred at that temperature for 10 min, then it was warmed to 15° C. and stirred for 18 h. The reaction was quenched with a saturated aqueous solution of NH4Cl and concentrated to about 300 mL. The solution was diluted with water and extracted with EtOAc. The EtOAc layer was dried over Na2SO4 and concentrated to give compound A2.2 (100 g, 90% yield). MS: calcd 306 (MH + ), measured value 306(MH + ).

[0059] Step 2: Preparation of 8-bromo-5-fluoro-1H-quinolin-2-one (compound A2.3) A solution of N-(2-bromo-5-fluoro-phenyl)-3,3-dimethoxy-propanamide (compound A2.2, 100 g, 238 mmol) in DCM (500 mL) was added to concentrated sulfuric acid (300 mL) at 0° C. The mixture was stirred at 15° C. for 2 h. The mixture was slowly poured into 2000 mL of ice water, and a yellow precipitate appeared. The mixture was filtered and the wet cake was washed with 500 mL of water, 200 mL of isopropyl alcohol, and 300 mL of PE. The solid was dried under reduced pressure to give compound A2.3 (50 g, 86.5% yield). MS: calculated 242 (MH + ), measured value 242(MH + ).

[0060] Step 3: Preparation of 5-fluoro-2-oxo-1H-quinoline-8-carbonitrile (Compound A2.4) A solution of 8-bromo-5-fluoro-1H-quinolin-2-one (compound A2.3, 50 g, 206 mmol), zinc cyanide (4820 mg, 412 mmol), Pd(PPh3)4 (2428 mg, 21 mmol) in DMF was stirred at 120° C. for 5 h. The reaction mixture was diluted with water and extracted with DCM. The organic layer was dried and concentrated to give the crude product, which was purified by flash column to give compound A2.4 (29 g, 74.5% yield). MS: calculated 189 (MH + ), measured value 189(MH + ).

[0061] Step 4: Preparation of (8-cyano-5-fluoro-2-quinolyl)trifluoromethanesulfonate (compound A2.5) To a solution of 5-fluoro-2-oxo-1H-quinoline-8-carbonitrile (compound A2.4, 17 g, 90 mmol) and 2,6-dimethylpyridine (39 g, 361 mmol) in DCM was added trifluoromethanesulfonic anhydride (51 g, 181 mmol) dropwise at 0° C. The mixture was stirred at 0° C. for 1 h, then the reaction was diluted with water and extracted with DCM. The organic layer was dried and concentrated. The residue was purified by flash column to give compound A2.5 (23.0 g, 80% yield). MS: calculated 321 (MH +), measured value 321(MH + ).

[0062] Step 5: Preparation of 2-deuterio-5-fluoro-quinoline-8-carbonitrile (Intermediate A2) To a solution of (8-cyano-5-fluoro-2-quinolyl)trifluoromethanesulfonate (compound A2.5, 23 g, 72 mmol) in THF (230 mL) and deuterium oxide (100 mL) was added potassium carbonate (20 g, 144 mmol) and Pd / C (6 g). The mixture was stirred at 40° C. under a deuterium atmosphere (balloon) for 5 h. The mixture was filtered and the filtrate was concentrated and purified by flash column to give intermediate A2 (11 g, 87.8% yield), which was used directly in the next step without further purification. MS: calculated 174 (MH + ), measured value 174(MH + ).

[0063] Intermediate B (4R)-4-Methyloctahydro-8H-pyrido[1,2-a]pyrazin-8-one 2,2,2-trifluoroacetate [ka]

[0064] The title compound was synthesized according to the following scheme. [ka]

[0065] Step 1: Preparation of tert-butyl N-[(1R)-2-(benzylamino)-1-methyl-ethyl]carbamate (Compound B2) To a solution of tert-butyl N-[(1R)-2-amino-1-methyl-ethyl]carbamate (compound B1, 135.0 g, 774.8 mmol) in DCE (3.0 L) was added benzaldehyde (71.0 mL, 695.8 mmol). The resulting mixture was stirred at room temperature for 2 h. Sodium triacetoxyborohydride (405.0 g, 1.9 mol) was added to the above solution. After stirring at room temperature overnight, the reaction mixture was neutralized to pH 8 with saturated Na2CO3(aq), diluted with water (1.0 L), and extracted twice with DCM (1.0 L). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography to give compound B2 (163.6 g, 80% yield). MS: calcd. 265 (MH + ), measured value 265(MH + ).

[0066] Step 2: Preparation of methyl (E)-4-[benzyl-[(2R)-2-(tert-butoxycarbonylamino)-propyl]-amino]but-2-enoate (Compound B3) To a solution of tert-butyl N-[(1R)-2-(benzylamino)-1-methyl-ethyl]carbamate (compound B2, 185.0 g, 699.8 mmol) in acetone (2.0 L) was added methyl 4-bromocrotonate (135.0 g, 754.2 mmol) and potassium carbonate (290.0 g, 2.1 mol). After stirring at room temperature overnight, the mixture was filtered through Celite and the filtrate was concentrated. The residue was purified by silica gel chromatography to give compound B3 (146.0 g, 57.6% yield). MS: calculated 363 (MH + ), measured value 363(MH + ).

[0067] Step 3: Preparation of methyl 2-[(6R)-4-benzyl-6-methyl-piperazin-2-yl]acetate (Compound B4) A mixture of methyl (E)-4-[benzyl-[(2R)-2-(tert-butoxycarbonylamino)propyl]amino]but-2-enoate (compound B3, 132.0 g, 364.2 mmol) and HCl / methanol (1N, 1.0 L) was heated to reflux for 2 h. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was neutralized to pH 10 with saturated K2CO3(aq), diluted with water (1.0 L), and extracted three times with DCM (1.0 L). The combined organic layers were washed twice with brine (1000 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography to give compound B4 (90.0 g, 94.0% yield). MS: calcd. 263 (MH + ), measured value 263(MH + ).

[0068] Step 4: Preparation of methyl 3-((6R)-4-benzyl-2-(2-methoxy-2-oxoethyl)-6-methylpiperazin-1-yl)propanoate (Compound B5) A solution of methyl 2-((6R)-4-benzyl-6-methylpiperazin-2-yl)acetate (compound B4, 50 g, 191 mmol,) and methyl acrylate (49.2 g, 51.5 mL, 572 mmol) was heated at 100 °C for 12 h. The reaction mixture was then concentrated and purified by silica gel chromatography (DCM / MeOH 1% to 20%) to give compound B5 (12.7 g, 19.1% yield) as a yellow oil. MS: calculated 349 (MH + ), measured value 349(MH + ).

[0069] Step 5: Preparation of (4R)-2-benzyl-4-methyloctahydro-8H-pyrido[1,2-a]pyrazin-8-one (Compound B6) To a stirred and cooled (ice water, 0° C.) suspension of potassium tert-butoxide (8.18 g, 72.9 mmol) in toluene (40 mL) was slowly added a solution of methyl 3-((6R)-4-benzyl-2-(2-methoxy-2-oxoethyl)-6-methylpiperazin-1-yl)propanoate (compound B5, 12.7 g, 36.4 mmol) in toluene (5 mL). The mixture was stirred at 0° C. for 2 h. The mixture was then extracted three times with 6N HCl (5 mL). The aqueous layer was stirred at 100° C. for 3 h, then it was cooled again to 0° C., neutralized with K2CO3, and extracted three times with EA (100 mL). The organic layers were combined, washed twice with saturated NaCl (20 mL), dried over Na2SO4, and concentrated in vacuo. The crude material was purified by flash chromatography (silica gel, 80 g, 20% to 80% EtOAc in PE) to give compound B6 (6.6 g, 70.4% yield) as a light yellow oil. MS: calculated 259 (MH + ), measured value 259(MH + ).

[0070] Step 6: Preparation of tert-butyl (4R)-4-methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazine-2-carboxylate (Compound B7) A solution of (4R)-2-benzyl-4-methyloctahydro-8H-pyrido[1,2-a]pyrazin-8-one (compound B6, 6.53 g, 25.3 mmol), boc anhydride (11 g, 11.7 mL, 50.5 mmol) and Pd-C (700 mg, 6.58 mmol) in MeOH (30 mL) was stirred at room temperature under H2 atmosphere for 3 h. It was then filtered and the filtrate was concentrated. The resulting residue was purified by silica gel chromatography (DCM / MeOH 2%-10%) to give compound B7 (6.6 g, 97% yield) as a white solid. MS: calculated 269 (MH + ), measured value 269(MH + ).

[0071] Step 7: Preparation of (4R)-4-methyloctahydro-8H-pyrido[1,2-a]pyrazin-8-one 2,2,2-trifluoroacetate (Intermediate B) To a solution of tert-butyl (4R)-4-methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazine-2-carboxylate (compound B7, 6.6 g, 24.6 mmol) in DCM (20 mL) was added a solution of 2,2,2-trifluoroacetic acid (2.8 g, 20 mL) at 0° C. The reaction mixture was stirred at rt for 12 h and then concentrated to give intermediate B (6.8 g, 98% yield) as a light yellow oil. MS: calculated 169 (MH + ), measured value 169(MH + ).

[0072] Intermediate C1 5-((4R,9aS)-4-Methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Intermediate C1) [ka]

[0073] The title compound was synthesized according to the following scheme. [ka]

[0074] Step 1: Preparation of (4R,8aS)-2-benzyl-4-methyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-ol (Intermediate C1) To a solution of DIPEA (9.34 g, 12.6 mL, 72.3 mmol) in DMSO (10 mL) was added 5-fluoroquinoline-8-carbonitrile (Intermediate A1, 4.15 g, 24.1 mmol) and (4R)-4-methyloctahydro-8H-pyrido[1,2-a]pyrazin-8-one 2,2,2-trifluoroacetate (Intermediate B, 6.8 g, 24.1 mmol). After stirring at 120° C. for 3 h, the mixture was cooled to room temperature, quenched with water (10 mL) and extracted twice with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography (silica gel, 20% to 80% PE in EtOAc) to give 5-((4R,9aS)-4-methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Intermediate C1, 2 g, 25.9% yield) as a yellow solid and 5-((4R,9aR)-4-methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Intermediate C2, 400 mg, 5.18% yield) as a yellow solid. The stereochemistry of intermediates C1 and C2 was confirmed by NOESY.

[0075] Intermediate C1: MS: Calculated 321 (MH + ), measured value 321(MH + ). 1 H NMR(DMSO-d6,400MHz)δ 9.04(dd,J=1.6,4.2Hz,1H), 8.53(dd J=1.7,8.6Hz,1H,), 8.24(d,J=8.1Hz,1H), 7.67(dd,J=4.3,8.6Hz,1H), 7.21(d,J=8.1Hz,1H), 3. 5-3.6(m,1H), 3.3-3.4(m,2H), 2.7-2.9(m,3H), 2.5-2.7(m,2H), 2.1-2.4(m,4H), 1.1-1.2(m,3H).

[0076] Intermediate C2: MS: Calculated 321 (MH + ), measured value 321(MH + ). 1H NMR(DMSO-d6,400MHz)δ 9.05(dd,J=1.7,4.2Hz,1H), 8.60(dd,J=1.6,8.6Hz,1H), 8.25(d,J=8.1Hz,1H ), 7.70(dd,J=4.2,8.6Hz,1H), 7.23(d,J=8.1Hz,1H), 3.4-3.5(m,1H), 3.28(br dd,J=2.7,11.5Hz,2H), 3.20(br dd,J=5.5,11.6Hz,1H), 3.06(br d,J=6.5Hz,1H), 2.7-2.9(m,2H), 2.6-2.7(m,1H), 2.65(dt,J=6.1,13.5Hz,2H), 2.23(td,J=2.6,14.2Hz,1H), 2.13(br d,1H,J=13.7Hz), 1.1-1.2(m,4H).

[0077] Intermediate D1 2-Deuterio-5-[(4R)-4-methyl-8-oxo-3,4,6,7,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate D1) [ka]

[0078] The title compound was synthesized according to the following scheme. [ka]

[0079] Step 1: Preparation of 2-deuterio-5-[(4R)-4-methyl-8-oxo-3,4,6,7,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate D1) To a solution of DIPEA (9.34 g, 12.6 mL, 72.3 mmol) in DMSO (10 mL) was added 2-deuterio-5-fluoro-quinoline-8-carbonitrile (Intermediate A2, 300 mg, 1.73 mmol) and (4R)-4-methyloctahydro-8H-pyrido[1,2-a]pyrazin-8-one 2,2,2-trifluoroacetate (Intermediate B, 537 mg, 1.90 mmol). After stirring at 120° C. for 3 h, the mixture was cooled to room temperature, quenched with water (10 mL) and extracted twice with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography (silica gel, 20% to 80% PE in EtOAc) to give 2-deuterio-5-[(4R)-4-methyl-8-oxo-3,4,6,7,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate D1, 500 mg) as a yellow solid. MS: calculated 322 (MH + ), measured value 322 (MH + ).

[0080] Examples 1 and 17 5-[(4R,8R,9aS)-4-Methyl-8-[(4-piperazin-1-ylphenyl)methylamino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Example 1) [ka] 5-[(4R,8S,9aS)-4-Methyl-8-[(4-piperazin-1-ylphenyl)methylamino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Example 17) [ka]

[0081] The title compound was prepared according to the following scheme. [ka]

[0082] Step 1: tert-Butyl 4-(4-((((4R,9aS)-2-(8-cyanoquinolin-5-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-8-yl)amino)methyl)phenyl)piperazine-1-carboxylate (Compound 1b) A solution of 5-((4R,9aS)-4-methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (intermediate C1, 32 mg, 99.9 μmol), tert-butyl 4-(4-(aminomethyl)phenyl)piperazine-1-carboxylate (compound 1a, CAS: 852180-47-3, vendor: Accela ChemBio Inc, 29 mg, 99.9 μmol) in MeOH (4 mL) was stirred at room temperature for 1 h. The reaction mixture was then cooled to 0° C. and sodium cyanotrihydroborate (12 mg, 200 μmol) was added. The reaction mixture was stirred at room temperature for 12 h. The mixture was quenched with water (10 mL) and extracted twice with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to give crude tert-butyl 4-(4-((((4R,9aS)-2-(8-cyanoquinolin-5-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-8-yl)amino)methyl)phenyl)piperazine-1-carboxylate (compound 1b, 50 mg), which was used in the next step without purification. MS: calcd. 596 (MH + ), measured value 596(MH + ).

[0083] Step 2: 5-[(4R,8R,9aS)-4-Methyl-8-[(4-piperazin-1-ylphenyl)methylamino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Example 1) 5-[(4R,8S,9aS)-4-Methyl-8-[(4-piperazin-1-ylphenyl)methylamino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Example 17) To a solution of tert-butyl 4-(4-((((4R,9aS)-2-(8-cyanoquinolin-5-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-8-yl)amino)methyl)phenyl)piperazine-1-carboxylate (compound 1b, 50 mg, 83.9 μmol) in DCM (4 mL) was added TFA (0.5 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 h. The mixture was then concentrated to the crude product, which was purified by preparative HPLC to give Example 1 (3 mg) as a light yellow solid and Example 17 (4 mg) as a light yellow solid.

[0084] Example 1: Stereochemistry confirmed by NOESY. MS: calculated 496 (MH + ), measured value 496(MH + ). 1 H NMR(400MHz, methanol-d4)δ 8.99(dd,J=1.7,4.2Hz,1H), 8.62(dd,J=1.7,8.6Hz,1H), 8.16(d,J=8.1Hz,1H),7. 65(dd,J=4.2,8.6Hz,1H), 7.26(dd,J=8.4,11.9Hz,3H), 6.98(d,J=8.7Hz,2H), 3.7 8(s,2H), 3.46-3.37(m,2H), 3.19-3.11(m,4H), 3.03-2.97(m,4H), 2.89-2.51(m,6 H), 2.15-1.92(m,3H), 1.58-1.45(m,1H), 1.33-1.23(m,1H), 1.19(d,J=6.2Hz,3H).

[0085] Example 17: Stereochemistry confirmed by NOESY. MS: calculated 496 (MH + ), measured value 496(MH + ). 1H NMR(400MHz, methanol-d4)δ 8.99(dd,J=1.7,4.2Hz,1H), 8.62(dd,J=1.7,8.6Hz,1H), 8.15(d,J=8.1Hz,1H), 7.65(dd,J= 4.2,8.6Hz,1H), 7.29(d,J=8.6Hz,2H), 7.22(d,J=8.1Hz,1H), 6.97(d,J=8.7Hz,2H), 3.81-3. 70(m,2H), 3.44-3.38(m,1H), 3.29-3.23(m,1H), 3.18-3.09(m,5H), 3.04-2.94(m,6H), 2.89- 2.71(m,3H), 2.50-2.41(m,1H), 1.96-1.69(m,3H), 1.59-1.50(m,1H), 1.19(d,J=5.9Hz,3H).

[0086] Example 2 5-[(4R,8R)-4-Methyl-8-(6-piperazin-1-yl-3-pyridyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0087] The title compound was prepared according to the following scheme. [ka]

[0088] Step 1: N'-((4R,E)-2-(8-cyanoquinolin-5-yl)-4-methyloctahydro-8H-pyrido[1,2-a]pyrazin-8-ylidene)-4-methylbenzenesulfonhydrazide (compound 2c) To a solution of 5-((4R)-4-methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Intermediate C1, 387 mg, 1.21 mmol) in ethanol (8 mL) was added 4-methylbenzenesulfonhydrazide (Compound 2b, 225 mg, 1.21 mmol). The reaction mixture was stirred at 25° C. for 3 h. LCMS showed consumed starting material. The reaction mixture was concentrated to give crude N′-((4R,E)-2-(8-cyanoquinolin-5-yl)-4-methyloctahydro-8H-pyrido[1,2-a]pyrazin-8-ylidene)-4-methylbenzenesulfonhydrazide (Compound 2c, 400 mg, 48.8% yield) as a yellow solid which could be used in the next step without purification. MS: calculated 489 (MH + ), measured value 489(MH + ).

[0089] Step 2: 5-((4R)-8-(6-bromopyridin-3-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (compound 2e) To a solution of N''-((4R,E)-2-(8-cyanoquinolin-5-yl)-4-methyloctahydro-8H-pyrido[1,2-a]pyrazin-8-ylidene)-4-methylbenzenesulfonhydrazide (compound 2c, 300 mg, 614 μmol) in 1,4-dioxane (2 mL) was added (6-bromopyridin-3-yl)boronic acid (compound 2d, 198 mg, 982 μmol), and CsCO (320 mg, 982 μmol). After stirring at 120° C. for 16 hours under N2 atmosphere, the mixture was then concentrated to give a crude product, which was purified by silica gel column (PE / EA=3 / 1) to give 5-((4R)-8-(6-bromopyridin-3-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (compound 2e, 50 mg, 17.6% yield) as a yellow oil. MS: calculated 463 (MH + ), measured value 463(MH + ).

[0090] Step 3: tert-Butyl 4-(5-((4R)-2-(8-cyanoquinolin-5-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-8-yl)pyridin-2-yl)piperazine-1-carboxylate (compound 2g) To a microwave tube was added 5-((4R)-8-(6-bromopyridin-3-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (compound 2e, 50 mg, 108 μmol), tert-butyl piperazine-1-carboxylate (compound 2f, 26.2 mg, 141 μmol), sodium tert-butoxide (162 μl, 324 μmol) and 1,4-dioxane (5 mL), the suspension was bubbled with N2 for 5 min, and tBuXPhos PD G3 (8.59 mg, 10.8 μmol) was added. After stirring at 100 °C for 12 h, the mixture was cooled to room temperature, quenched with saturated NaHCO3 (5 mL) solution and extracted three times with EtOAc (10 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 15% DCM in MeOH) to give tert-butyl 4-(5-((4R)-2-(8-cyanoquinolin-5-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-8-yl)pyridin-2-yl)piperazine-1-carboxylate (Compound 2g, 30 mg, 52.8 μmol) as an orange solid. MS: calcd. 568 (MH + ), measured value 568(MH + ).

[0091] Step 4: 5-[(4R,8R)-4-methyl-8-(6-piperazin-1-yl-3-pyridyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Example 2) To a solution of tert-butyl 4-(5-((4R)-2-(8-cyanoquinolin-5-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-8-yl)pyridin-2-yl)piperazine-1-carboxylate (compound 2g, 30 mg, 52.8 μmol) in DCM (4 mL) was added TFA (0.5 mL) at 0° C. The mixture was then concentrated to the crude product, which was purified by preparative HPLC to give Example 2 (2 mg) as a light yellow solid. MS calculated 468 (MH + ), measured value 468(MH + ). 1 H NMR(400MHz, methanol-d4)δ 8.90(dd,J=1.7,4.3Hz,1H), 8.56(dd,J=1.6,8.6Hz,1H), 8.06(d,J=7.9Hz,1H), 7.96(d,J=2.2Hz,1H), 7.56( dd,J=4.3,8.7Hz,1H), 7.47(dd,J=2.5,8.7Hz,1H), 7.16(d,J=8.1Hz,1H), 6.76(d,J=8.7Hz,1H), 3.50-3.43(m ,4H), 3.37-3.29(m,2H), 3.00-2.93(m,4H), 2.82-2.74(m,2H), 2.70-2.64(m,2H), 2.18-2.08(m,1H), 1.91-1. 84(m,1H), 1.78-1.67(m,2H), 1.52-1.40(m,1H), 1.23-1.21(m,1H), 1.20-1.17(m,1H), 1.14(d,J=6.0Hz,3H).

[0092] Example 3 5-[(4R,8R)-4-Methyl-8-(4-piperazin-1-ylphenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0093] The title compound was prepared similarly to the preparation of Example 2 by using (4-bromophenyl)boronic acid instead of (6-bromopyridin-3-yl)boronic acid (compound 2d). Example 3 (17 mg) was obtained as a light grey solid. The stereochemistry was confirmed by NOESY. MS: calculated 467 (MH + ), measured value 467(MH + ). 1 H NMR(400MHz, methanol-d4)δ 9.07-9.00(m,1H), 8.71(dd,J=1.7,8.6Hz,1H), 8.26-8.18(m,1H), 7.76-7.66(m,1H), 7.38(d,J=8.1Hz,1H), 7.29-7.22(m,2H) ), 7.08-7.00(m,2H), 4.26-4.05(m,1H), 4.03-3.80(m,2H), 3.79-3.64(m,2H), 3.63-3.49(m,1H), 3.48-3.34(m,8H), 3.24(br d,J=11.7Hz,4H), 2.31-1.98(m,3H), 1.93-1.84(m,1H), 1.84-1.78(m,1H), 1.54(d,J=6.5Hz,1H).

[0094] Example 4 5-[(4R,8R,9aS)-4-Methyl-8-(6-piperazin-1-yl-3-pyridyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0095] The title compound was prepared similarly to the preparation of Example 2 by using (6-bromopyridin-3-yl)boronic acid instead of (6-bromopyridin-3-yl)boronic acid (compound 2d). Example 4 (8 mg) was obtained as a brown solid. The stereochemistry was confirmed by NOESY. MS: calculated 468 (MH + ), measured value 468(MH + ). 1H NMR(400MHz, methanol-d4)δ 8.91(dd,J=1.6,4.3Hz,1H), 8.59(dd,J=1.7,8.6Hz,1H), 8.09(d,J=7.9Hz,1H), 8.00(d,J=2.3Hz,1H), 7 .67(dd,J=2.3,9.0Hz,1H), 7.59(dd,J=4.3, 8.7Hz,1H), 7.27(d,J=8.1Hz,1H), 7.01(d,J=8.9Hz,1H), 4.0 3-3.96(m,1H), 3.86-3.78(m,1H), 3.77-3.69(m,5H), 3.67-3.54(m,2H), 3.30-3.24(m,4H), 3.18-3.08(m ,3H), 3.08-2.97(m,1H), 2.19-2.07(m,2H), 2.03-1.91(m,1H), 1.86-1.75(m,1H), 1.43(d,J=6.4Hz,3H).

[0096] Example 6 5-[(4R,8R,9aS)-8-[6-[(3S,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0097] The title compound was prepared similarly to the preparation of Example 2, using tert-butyl N-[(3S,4S)-4-methoxypyrrolidin-3-yl]carbamate (CAS: 1627185-88-9, PharmaBlock, catalog #PBZ4724) instead of tert-butyl piperazine-1-carboxylate (compound 2f). Example 6 (21 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 498 (MH + ), measured value 498(MH + ). 1H NMR(400MHz, methanol-d4)δ 9.00(dd,J=1.5,4.3Hz,1H), 8.68(dd,J=1.6,8.7Hz,1H), 8.18(d,J=7.9Hz,1H), 8.03(dd,J=2.0,9.3Hz,1H), 7.93(d,J=2.0Hz) ,1H), 7.68(dd,J=4.3,8.6Hz,1H), 7.36(d,J=8.1Hz,1H), 7.12(d,J=9.3Hz,1H), 4.30-4.23(m,1H), 4.14-3.99(m,4H), 3.92(br s,1H), 3.88-3.79(m,2H), 3.79-3.62(m,3H), 3.49(s,3H), 3.29-3.12(m,4H), 2 .31-2.19(m,2H), 2.16-2.04(m,1H), 2.01-1.89(m,1H), 1.53(d,J=6.5Hz,3H).

[0098] Example 7 5-[(4R,8R,9aS)-8-[6-(3-aminoazetidin-1-yl)-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0099] The title compound was prepared similarly to the preparation of Example 2 by using tert-butyl N-[(3S,4S)-4-methoxypyrrolidin-3-yl]carbamate (CAS: 1627185-88-9, PharmaBlock, catalog #PBZ4724) instead of tert-butyl piperazine-1-carboxylate (compound 2f). Example 7 (14 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 454 (MH + ), measured value 454(MH + ). 1 H NMR 1H NMR(400MHz, methanol-d4)δ 9.05(dd,J=4.3,1.6Hz,1H), 8.70(dd,J=8.6,1.6Hz,1H), 8.23(d,J=7.9Hz,1H), 7.9 8(d,J=2.0Hz,1H), 7.90(dd,J=9.0,2.2Hz,1H), 7.72(dd,J=8.6,4.3Hz,1H), 7.39(d, J=8.1Hz,1H), 6.84(d,J=9.0Hz,1H), 4.58(dd,J=9.8,7.2Hz,2H), 4.37-4.22(m,3H), 4.16-4.08(m,1H), 3.98-3.80(m,2H), 3.80-3.64(m,2H), 3.27-3.07(m,4H), 2.21(br s,2H), 2.13-1.99(m,1H), 1.90(br d,J=14.1Hz,1H), 1.54(d,J=6.5Hz,3H).

[0100] Example 9 5-[(4R,8R,9aS)-4-Methyl-8-[3-(4-piperazin-1-ylphenyl)azetidin-1-yl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0101] The title compound was prepared according to the following scheme. [ka]

[0102] Step 1: 5-[(4R,8R,9aS)-8-[3-(4-bromophenyl)azetidin-1-yl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 9b) A solution of 5-((4R,9aS)-4-methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Intermediate C1, 30 mg, 93 μmol), 3-(4-bromophenyl)azetidine (Compound 9a, 20 mg, 93 μmol) in MeOH (10 mL) was stirred at room temperature for 1 h. The reaction mixture was then cooled to 0° C. and sodium cyanotrihydroborate (17 mg, 281 μmol) was added. After stirring at room temperature for 12 h, the mixture was quenched with water (10 mL) and extracted twice with EA. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to give the crude product, which was purified by preparative HPLC to give 5-[(4R,8R,9aS)-8-[3-(4-bromophenyl)azetidin-1-yl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 9b, 20 mg). MS: calculated 517 (MH + ), found to be 517 (MH+). The stereochemistry was confirmed by NOESY.

[0103] Step 2: tert-Butyl 4-[4-[1-[(4R,8R,9aS)-2-(8-cyano-5-quinolyl)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-8-yl]azetidin-3-yl]phenyl]piperazine-1-carboxylate (compound 9d) A mixture of 5-[(4R,8R,9aS)-8-[3-(4-bromophenyl)azetidin-1-yl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 9b, 20 mg, 38.7 μmol), tert-butyl piperazine-1-carboxylate (compound 9c, 9.38 mg, 50.3 μmol), tBuXPhos Pd G3 (1.54 mg, 1.94 μmol) and sodium tert-butoxide (18.6 mg, 194 μmol) in 1,4-dioxane (10 mL) was charged with N2. After stirring at 90 °C overnight, the mixture was cooled to room temperature and the solid was filtered off and washed twice with EA (10 mL). The filtrate was purified to give crude product tert-butyl 4-[4-[1-[(4R,8R,9aS)-2-(8-cyano-5-quinolyl)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-8-yl]azetidin-3-yl]phenyl]piperazine-1-carboxylate (compound 9d, 25 mg), which can be used in the next step without purification. MS: calculated 622 (MH + ), measured value 622(MH + ).

[0104] Step 3: 5-[(4R,8R,9aS)-4-Methyl-8-[3-(4-piperazin-1-ylphenyl)azetidin-1-yl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Example 9) To a solution of tert-butyl 4-[4-[1-[(4R,8R,9aS)-2-(8-cyano-5-quinolyl)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-8-yl]azetidin-3-yl]phenyl]piperazine-1-carboxylate (compound 9d, 25 mg) in DCM (4 mL) was added TFA (0.5 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 h. The mixture was then concentrated to the crude product, which was purified by preparative HPLC to give Example 9 (11 mg) as a light yellow solid. MS: calculated 522 (MH +), measured value 522(MH + ). 1 H NMR(400MHz, methanol-d4)δ 8.92(dd,J=4.3,1.6Hz,1H), 8.55(dd,J=8.6,1.7Hz,1H), 8.09(d,J=7.9Hz,1H), 7.58(d d,J=8.6,4.3Hz,1H), 7.25(t,J=8.4Hz,3H), 6.92-7.04(m,2H), 4.35-4.51(m,2H), 4.11 -4.30(m,2H), 3.80-4.07(m,2H), 3.38-3.71(m,5H), 3.26-3.37(m,6H), 2.90-3.12(m,2 H), 2.69-2.85(m,1H), 2.18-2.42(m,2H), 1.47-1.81(m,2H), 1.32ppm(d,J=6.4Hz,3H).

[0105] Example 11 5-[(4R,8S,9aS)-4-Methyl-8-[(5-piperazin-1-yl-2-pyridyl)oxy]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0106] The title compound was prepared according to the following scheme. [ka]

[0107] Step 1: 5-((4R,8R)-8-hydroxy-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Compound 11a) To a solution of 5-((4R)-4-methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Intermediate C1, 500 mg, 1.56 mmol) in MeOH (10 mL) was added sodium tetrahydroborate (70.8 mg, 1.87 mmol). After stirring at room temperature for 2 h, the reaction was carefully quenched with 10% HCl solution. The resulting mixture was neutralized with K2CO3 and extracted twice with EtOAc (30 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to give 5-((4R,8R)-8-hydroxy-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Compound 11a, 500 mg), which was used directly in the next step without further purification. The stereochemistry was confirmed by NOESY. MS: calculated 323 (MH + ), measured value 323 (MH + ). 1H NMR(DMSO-d6,400MHz)δ 9.03(dd,1H,J=1.6,4.2Hz), 8.51(dd,1H,J=1.5,8.6Hz), 8.22(d,1H,J=8.1Hz), 7.67(dd,1H,J=4.3, 8.6 Hz), 7.18(d,1H,J=8.2Hz), 4.69(d,1H,J=4.6Hz), 3.48(dt,1H,J=5.6, 10.4Hz), 3.2-3.3(m,1H), 3.20(br d,1H,J=11.4Hz), 2.6-2.8(m,2H), 2.3-2.4(m,1H), 1.7-1.9(m,3H), 1.3-1.5(m,1H), 1.0-1.1(m,1H), 1.0-1.1(m,3H).

[0108] Step 2: 5-((4R,8S,9aS)-8-((5-chloropyridin-2-yl)oxy)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (compound 11c) A solution of 5-((4R,9aS)-8-hydroxy-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (compound 11a, 60 mg, 186 μmol), 5-chloropyridin-2-ol (compound 11b, 24 mg, 186 μmol) and PPh3 (98 mg, 372 μmol) in THF (4 mL) at 0° C. was treated with DIAD (72 μL, 372 μmol) and stirred at room temperature for 1 h. After stirring at 70° C. for 1 h, the mixture was cooled to room temperature, diluted with EtOAc, washed with water and brine, dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (20% to 100% EtOAc / PE) to give 5-((4R,8S,9aS)-8-((5-chloropyridin-2-yl)oxy)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Compound 11c, 40 mg) as a pale yellow solid. MS: calculated 434 (MH + ), measured value 434(MH + ). The stereochemistry was confirmed by NOESY.

[0109] Step 3: tert-Butyl 4-(6-(((4R,8S,9aS)-2-(8-cyanoquinolin-5-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-8-yl)oxy)pyridin-3-yl)piperazine-1-carboxylate (Compound 11e) To a microwave tube was added 5-((4R,8S,9aS)-8-((5-chloropyridin-2-yl)oxy)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (compound 11c, 40 mg, 92.2 μmol), tert-butyl piperazine-1-carboxylate (compound 11d, 22 mg, 120 μmol), sodium tert-butoxide (138 μL, 277 μmol, 2M in THF) and 1,4-dioxane (5 mL), the suspension was bubbled with N2 for 5 min, and tBuXPhos PD G3 (7 mg, 9.22 μmol) was added. After stirring at 100 °C for 12 h, the mixture was cooled to room temperature, diluted with saturated NaHCO3 (5 mL) solution and extracted three times with EtOAC (10 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated to give tert-butyl 4-(6-(((4R,8S,9aS)-2-(8-cyanoquinolin-5-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-8-yl)oxy)pyridin-3-yl)piperazine-1-carboxylate (compound 11e, 20 mg) as an orange solid which can be used in the next step without purification. MS: calcd. 584 (MH + ), measured value 584(MH + ).

[0110] Step 4: 5-[(4R,8S,9aS)-4-Methyl-8-[(5-piperazin-1-yl-2-pyridyl)oxy]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Example 11) To a solution of tert-butyl 4-(6-(((4R,8S,9aS)-2-(8-cyanoquinolin-5-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-8-yl)oxy)pyridin-3-yl)piperazine-1-carboxylate (compound 11e, 20 mg) in DCM (2 mL) was added TFA (0.5 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 h. The mixture was then concentrated to the crude product, which was purified by preparative HPLC to give Example 11 (16 mg) as a light brown solid. MS: calculated 484 (MH + ), measured value 484(MH + ). 1 H NMR(400MHz, methanol-d4)δ 9.02(dd,J=4.2,1.7Hz,1H), 8.70(dd,J=8.6,1.7Hz,1H), 8.20(d,J=8.1Hz,1H), 7.89(d,J=2.9Hz,1H), 7.6 9(dd,J=8.7,4.3Hz,1H), 7.57(dd,J=9.0,3.1Hz,1H), 7.38(d,J=8.1Hz,1H), 6.93(d,J=8.9Hz,1H), 5.45(br s,1H), 4.17-4.09(m,1H), 4.00-3.87(m,2H), 3.78-3.71(m,1H), 3.66-3.59(m,1H), 3.45-3.34(m,9H), 3.2 1(td,J=14.0, 11.1Hz,2H), 2.48-2.36(m,2H), 2.27-2.16(m,1H), 2.12-2.01(m,1H), 1.52(d,J=6.5Hz,3H).

[0111] Example 12 5-[(4R,8R,9aS)-8-[6-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0112] The title compound was prepared similarly to the preparation of Example 2 by using tert-butyl ((3R,4S)-4-methoxypyrrolidin-3-yl)carbamate (CAS: 1932508-77-4, PharmaBlock) instead of tert-butyl piperazine-1-carboxylate (compound 2f). Example 12 (9 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 498 (MH + ), measured value 498(MH + ). 1 H NMR(400MHz, methanol-d4)δ 9.02(dd,J=4.3,1.6Hz,1H), 8.70(dd,J=8.6,1.6Hz,1H), 8.20(d,J=8.1Hz,1H), 8.06(dd, J=9.4,2.0Hz,1H), 7.99-7.94(m,1H), 7.70(dd,J=8.6,4.3Hz,1H), 7.38(d,J=8.1Hz,1H), 7 .14(d,J=9.4Hz,1H), 4.36(dt,J=4.5,2.3Hz,1H), 4.22-4.04(m,3H), 3.99-3.65(m,7H), 3. 53(s,3H), 3.31-3.14(m,4H), 2.34-2.07(m,3H), 2.05-1.92(m,1H), 1.55(d,J=6.5Hz,3H).

[0113] Example 13 5-[(4R,8R,9aS)-8-[6-[(3S,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0114] The title compound was prepared similarly to the preparation of Example 2 by using tert-butyl ((3S,4R)-4-methoxypyrrolidin-3-yl)carbamate (CAS: 1931911-57-7, PharmaBlock, catalog #PBZ4730) instead of tert-butyl piperazine-1-carboxylate (compound 2f). Example 13 (15 mg) was obtained as a pale yellow solid. Stereochemistry was confirmed by NOESY. MS: calculated 498 (MH + ), measured value 498(MH + ). 1 H NMR(400MHz, methanol-d4)δ 9.02(dd,J=4.2, 1.5Hz,1H), 8.70(dd,J=8.6,1.6Hz,1H), 8.20(d,J=7.9Hz,1H), 8.06(dd,J=9.4,2. 0Hz,1H), 7.99-7.93(m,1H), 7.70(dd,J=8.6,4.3Hz,1H), 7.38(d,J=7.9Hz,1H), 7.14(d,J=9.3Hz,1H) ), 4.36(td,J=4.5,2.4Hz,1H), 4.21-4.05(m,3H), 3.99-3.90(m,2H), 3.89-3.79(m,2H), 3.78-3.65( m,3H), 3.53(s,3H), 3.31-3.14(m,4H), 2.34-2.07(m,3H), 2.04-1.92(m,1H), 1.55(d,J=6.4Hz,3H).

[0115] Example 14 5-[(4R,8R,9aS)-8-[6-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0116] The title compound was prepared similarly to the preparation of Example 2 by using tert-butyl ((3R,4R)-4-methoxypyrrolidin-3-yl)carbamate (CAS: 1932066-52-8, PharmaBlock, catalog #PBZ4728) instead of tert-butyl piperazine-1-carboxylate (compound 2f). Example 13 (10 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 498 (MH + ), measured value 498(MH + ). 1 H NMR(400MHz, methanol-d4)δ 9.04(dd,J=4.2, 1.5Hz,1H), 8.71(dd,J=8.6,1.7Hz,1H), 8.22(d,J=7.9Hz,1H), 8.01-7.95(m,2H) , 7.71(dd,J=8.6,4.2Hz,1H), 7.39(d,J=7.9Hz,1H), 7.06(d,J=10.0Hz,1H), 4.26(dt,J=5.5,2.8H z,1H), 4.16-4.09(m,1H), 4.09-3.99(m,3H), 3.98-3.82(m,2H), 3.82-3.66(m,4H), 3.51(s,3H), 3 .30-3.13(m,4H), 2.34-2.20(m,2H), 2.16-2.03(m,1H), 2.00-1.88(m,1H), 1.55(d,J=6.4Hz,3H).

[0117] Example 15 5-[(4R,8R,9aR)-4-Methyl-8-(6-piperazin-1-yl-3-pyridyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0118] The title compound was prepared similarly to the preparation of Example 2 by using 5-((4R,8R,9aR)-8-(6-bromopyridin-3-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile instead of 5-((4R)-8-(6-bromopyridin-3-yl)-4-methyloctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (compound 2e). Example 15 (4 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calcd 468 (MH + ), measured value 468(MH + ). 1 H NMR(400MHz, methanol-d4)δ 8.99(dd,J=4.2,1.7Hz,1H), 8.73(dd,J=8.6,1.7Hz,1H), 8.16(d,J=8.1Hz,1H), 8.03(d,J =2.3Hz,1H), 7.66(dd,J=8.6,4.3Hz,1H), 7.54(dd,J=8.7, 2.4Hz,1H), 7.27(d,J=8.1Hz,1 H), 6.83(d,J=8.7Hz,1H), 3.52-3.35(m,8H), 3.31-3.26(m,1H), 3.25-3.14(m,1H), 2.98- 2.82(m,6H), 2.80-2.65(m,2H), 1.93-1.77(m,2H), 1.65-1.49(m,1H), 1.48-1.43(m,3H).

[0119] Example 16 5-[(4R,8S,9aS)-4-Methyl-8-[(6-piperazin-1-yl-3-pyridyl)oxy]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0120] The title compound was prepared similarly to the preparation of Example 11 by using 5-bromo-2-hydroxypyridine (PharmaBlock, CAS: 13466-38-1) instead of 5-chloropyridin-2-ol (Compound 11b). Example 16 (50 mg) was obtained as a white solid. The stereochemistry was confirmed by NOESY. MS: calculated 484 (MH + ), measured value 484(MH + ). 1 H NMR(400MHz, methanol-d4)δ 8.94(dd,J=4.2,1.6Hz,1H), 8.57(dd,J=8.6,1.6Hz,1H), 8.11(d,J=7.9Hz,1H), 7.76(d,J=2.8Hz,1H), 7.61(dd,J=8.6 ,4.2Hz,1H), 7.45(dd,J=8.9,3.1Hz,1H), 7.20(d,J=7.9Hz,1H), 6.79(d,J=8.9Hz,1H), 5.21(t,J=2.4Hz,1H), 3.40(br d,J=11.2Hz,1H), 3.26(br d,J=11.7Hz,1H), 3.21-3.15(m,1H), 3.07-3.01(m,4H), 3.01-2.94(m,5H), 2.85-2.72(m,3H), 2. 49-2.36(m,1H), 2.14-2.06(m,1H), 2.01-1.87(m,2H), 1.70-1.61(m,1H), 1.18(d,J=5.9Hz,3H).

[0121] Example 18 5-[(4R,8S,9aS)-4-Methyl-8-(2-piperazin-1-ylpyrimidin-5-yl)oxy-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0122] The title compound was prepared similarly to the preparation of Example 11 by using 2-chloro-5-hydroxypyrimidine (Accela ChemBio Inc, CAS: 4983-28-2) instead of 5-chloropyridin-2-ol (Compound 11b). Example 18 (27 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 485 (MH + ), measured value 485(MH + ). 1 H NMR(400MHz, methanol-d4)δ 9.04(dd,J=4.2, 1.7Hz,1H), 8.71(dd,J=8.6,1.7Hz,1H), 8.37(s,2H), 8.22( d,J=7.9Hz,1H), 7.71(dd,J=8.6, 4.3Hz,1H), 7.38(d,J=7.9Hz,1H), 4.79(br s,1H), 4.21-4.12(m,1H), 4.06-4.00(m,4H), 3.99-3.87(m,2H), 3.79-3.72(m,1H), 3.70-3.62(m,1H), 3.50-3.40(m,1H), 3.3 2-3.28(m,4H), 3.21(td,J=13.7, 11.2Hz,2H), 2.42-2.35(m,2H), 2.25-2.13(m,1H), 2.10-2.00(m,1H), 1.52(d,J=6.5Hz,3H).

[0123] Example 19 5-[(4R,8R,9aS)-8-[6-[(3R,4S)-3-amino-4-fluoro-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0124] The title compound was prepared similarly to the preparation of Example 2 by using tert-butyl N-[(3R,4S)-4-fluoropyrrolidin-3-yl]carbamate (CAS: 1033718-91-0, PharmaBlock, catalog #PB09204) instead of tert-butyl piperazine-1-carboxylate (compound 2f). Example 19 (5 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 486 (MH + ), measured value 486(MH + ). 1 H NMR(400MHz, methanol-d4)δ 9.04(dd,J=4.3,1.6Hz,1H), 8.71(dd,J=8.6,1.6Hz,1H), 8.22(d,J=7.9Hz,1H), 8.05(dd,J=9.2,2. 3Hz,1H), 8.00(d,J=1.8Hz,1H), 7.71(dd,J=8.6,4.3Hz,1H), 7.39(d,J=7.9Hz,1H), 7.12(d,J=9.3Hz) ,1H), 5.69-5.51(m,1H), 4.34-4.20(m,2H), 4.17-4.03(m,3H), 4.00-3.80(m,3H), 3.79-3.65(m,3H) , 3.31-3.14(m,4H), 2.34-2.21(m,2H), 2.19-2.06(m,1H), 2.03-1.91(m,1H), 1.55(d,J=6.4Hz,3H).

[0125] Example 20 5-[(4R,8R,9aS)-4-Methyl-8-[4-[(2S)-morpholin-2-yl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0126] The title compound was prepared similarly to the preparation of Example 1 by using tert-butyl (2S)-2-(4-aminophenyl)morpholine-4-carboxylate instead of tert-butyl 4-(4-(aminomethyl)phenyl)piperazine-1-carboxylate (compound 1a) in step 1. Example 20 (7 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calcd 483 (MH + ), measured value 483(MH + ). 1 H NMR(400MHz, methanol-d4)δ 9.04(dd,J=4.3,1.6Hz,1H), 8.71(dd,J=8.6,1.6Hz,1H), 8.22(d,J=7.9Hz,1H), 7.72(dd,J=8.6,4.3Hz,1H), 7.38(d,J=8.1Hz,1H), 7.20(d,J =8.6Hz,2H), 6.75(d,J=8.6Hz,2H), 4.60(dd,J=11.2,2.1Hz,1H), 4.21(dd,J=12.9,3.1Hz,1H), 3.60-4.12(m,7H), 3.05-3.25(m,8H), 2.44(br t,J=14.7Hz,2H), 1.68-1.90(m,1H), 1.45(s,3H).

[0127] Example 21 5-[(4R,8R,9aS)-4-Methyl-8-[4-[[(2R)-morpholin-2-yl]methyl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0128] The title compound was prepared similarly to the preparation of Example 1 by using tert-butyl (2R)-2-[(4-aminophenyl)methyl]morpholine-4-carboxylate instead of tert-butyl 4-(4-(aminomethyl)phenyl)piperazine-1-carboxylate (compound 1a) in step 1. Example 21 (8 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 497 (MH + ), measured value 497(MH + ). 1 H NMR(400MHz, methanol-d4)δ 9.04(dd,J=4.2,1.7Hz,1H), 8.71(dd,J=8.6,1.7Hz,1H), 8.22(d,J=7.9Hz,1H), 7.72(dd,J= 8.6,4.3Hz,1H), 7.38(d,J=8.1Hz,1H), 7.06(d,J=8.6Hz,2H), 6.73(d,J=8.4Hz,2H), 4.07(br dd,J=13.0,3.5Hz,2H), 3.63-3.99(m,7H), 3.03-3.27(m,6H), 2.61-2.92(m ,3H), 2.32-2.54(m,2H), 1.68-1.88(m,1H), 1.56-1.60(m,1H), 1.40(s,3H).

[0129] Example 22 5-[(4R,8R,9aS)-4-Methyl-8-[4-[[(2R)-morpholin-2-yl]methyl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile [ka]

[0130] The title compound was prepared similarly to the preparation of Example 1 by using tert-butyl (R)-2-(4-aminobenzyl)morpholine-4-carboxylate and 2-deuterio-5-[(4R)-4-methyl-8-oxo-3,4,6,7,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate D1) instead of tert-butyl 4-(4(aminomethyl)phenyl)piperazine-1-carboxylate (Compound 1a) and 5-((4R,9aS)-4-methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Intermediate C1). Example 22 (39 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 498 (MH + ), measured value 498(MH + ). 1 H NMR(400MHz, methanol-d4)δ 8.67(d,J=8.7Hz,1H), 8.17(d,J=8.1Hz,1H), 7.68(d,J=8.6Hz,1H), 7.31(d,J=7.9Hz,1H),7. 04(d,J=8.4Hz,2H), 6.69(d,J=8.6Hz,2H), 4.06(dd,J=12.8,3.5Hz,1H), 3.88-3.38(m,9H), 3 .28-3.19(m,2H), 3.16-3.01(m,3H), 2.87(dd,J=12.7, 11.1Hz,1H), 2.82-2.75(m,1H), 2.71- 2.63(m,1H), 2.39-2.24(m,2H), 1.75-1.62(m,1H), 1.51-1.43(m,1H), 1.40(d,J=6.4Hz,3H).

[0131] Example 23 5-[(4R,8R,9aS)-8-[6-[(6S)-6-amino-1,4-oxazepan-4-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0132] The title compound was prepared similarly to the preparation of Example 2 by using tert-butyl N-[(6S)-1,4-oxazepan-6-yl]carbamate (PharmaBlock, catalog #PB97931) instead of tert-butyl piperazine-1-carboxylate (compound 2f). Example 23 (1 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 498 (MH + ), measured value 498(MH + ). 1 H NMR(400MHz, methanol-d4)δ 8.92(dd,J=4.2, 1.5Hz,1H), 8.59(dd,J=8.6,1.6Hz,1H), 8.10(d,J=7.9Hz,1H), 7.98(d,J=2.3H) z,1H), 7.60(dd,J=8.6,4.3Hz,1H), 7.51(dd,J=8.9,2.5Hz,1H), 7.27(d,J=7.9Hz,1H), 6.79(d, J=8.8Hz,1H), 4.17-4.08(m,1H), 4.02-3.88(m,3H), 3.85-3.52(m,10H), 3.17-3.07(m,2H), 3.0 7-2.90(m,2H), 2.18-2.05(m,2H), 2.02-1.91(m,1H), 1.83-1.71(m,1H), 1.42(d,J=6.4Hz,3H).

[0133] Examples 24 and 27 5-[(4R,8S,9aS)-4-Methyl-8-(4-morpholin-2-ylphenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Example 24) [ka] 5-[(4R,8R,9aS)-4-Methyl-8-[4-[(2R)-morpholin-2-yl]phenyl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Example 27) [ka]

[0134] The title compound was prepared similarly to the preparation of Example 2 by using tert-butyl (R)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpholine-4-carboxylate instead of 6-bromopyridin-3-yl)boronic acid (compound 2d). Example 24 (11 mg) was obtained as a light yellow solid, and Example 27 (17 mg) was obtained as a light yellow solid.

[0135] Example 24 Stereochemistry confirmed by NOESY. MS: calculated 468 (MH + ), measured value 468(MH + ). 1 H NMR (400 MHz, methanol-d4) δ 9.03-8.98 (m, 1H), 8.70 (dd, J = 8.6, 1.5 Hz, 1H), 8.59 (dd, J = 8.6, 1.4 Hz, 1H), 8.73-8.56 (m, 1H), 8.23-8.20 (m, 1H), 8.18 (br d,J=7.9Hz,1H), 8.24-8.16(m,1H), 7.71-7.63(m,1H), 7.58-7.46(m,2H) , 7.45-7.33(m,2H), 4.79(ddd,J=16.6,11.3,2.0Hz,1H), 4.26(dt,J=12.6 ,4.2Hz,1H), 4.44-4.20(m,1H), 4.09-3.63(m,5H), 3.60-3.41(m,3H), 3. 18-3.01(m,2H), 2.74-2.60(m,1H), 2.51-2.01(m,3H), 1.52-1.43(m,3H).

[0136] Example 27 Stereochemistry confirmed by NOESY. MS: calculated 468 (MH + ), measured value 468(MH + ). 1H NMR(400MHz, methanol-d4)δ 9.05-9.01(m,1H), 8.71(dd,J=8.6, 1.5Hz,1H), 8.21(d,J=7.9Hz,1H), 7.71(dd,J=8.6,4.3Hz,1H), 7.45-7.36(m,5H), 4.7 7(dd,J=11.2,2.3Hz,1H), 4.26(dd,J=13.0,3.3Hz,1H), 4.15-4.08(m,1H), 4.05-3.81(m,3H), 3.80-3.65(m,2H), 3.46(br d,J=13.0Hz,1H), 3.40-3.35(m,1H), 3.31-3.05(m,6H), 2.32-2.19(m,2H), 2.16-2.02(m,1H), 1.93(q, J=13.1Hz,1H), 1.54(d,J=6.4Hz,3H).

[0137] Examples 25 and 26 5-[(4R,8R,9aS)-4-Methyl-8-[4-[[(2R)-morpholin-2-yl]methyl]phenyl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Example 25) [ka] 5-[(4R,8S,9aS)-4-Methyl-8-[4-(morpholin-2-ylmethyl)phenyl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Example 26) [ka]

[0138] The title compound was prepared similarly to the preparation of Example 2 by using tert-butyl (R)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpholine-4-carboxylate instead of 6-bromopyridin-3-yl)boronic acid (Compound 2d). Example 25 (15 mg) was obtained as a light yellow solid, and Example 26 (8 mg) was obtained as a light yellow solid.

[0139] Example 25: Stereochemistry confirmed by NOESY. MS: calculated 482 (MH + ), measured value 482(MH + ). 1 H NMR(400MHz, methanol-d4)δ 9.02(dd,J=4.3, 1.6Hz,1H), 8.71(dd,J=8.6,1.7Hz,1H), 8.20(d,J=8.1Hz,1H), 7.70(dd,J=8.6,4.3Hz,1H), 7.38(d,J=8.1Hz,1H), 7.27(s,4H), 4.14-4.02(m,2 H), 3.98-3.83(m,3H), 3.83-3.64(m,3H), 3.29-3.08(m,7H), 2.97-2.77(m,3H), 2.31-2.17(m,2H), 2.15-2.01(m,1H), 1.98-1.86(m,1H), 1.54(d,J=6.5Hz,3H).

[0140] Example 26: Stereochemistry confirmed by NOESY. MS: Calculated 482 (MH + ), measured value 482(MH + ). 1H NMR (400 MHz, methanol-d4) δ 9.04-8.99 (m, 1H), 8.73-8.58 (m, 1H), 8.21 (dd, J = 10.1, 8.0 Hz, 1H), 7.68 (ddd, J = 13.0, 8.6, 4.3 Hz, 1H), 7.52-7.31 (m, 3H), 7.25 (s, 2H), 4.42-4.20 (m, 1H), 4.1 0-3.65(m,7H), 3.60-3.41(m,2H), 3.30-3.22(m,2H), 3.18-3.04(m,3H), 2.98-2 .81(m,3H), 2.74-2.59(m,1H), 2.48-1.98(m,3H), 1.47(dd,J=14.2,6.7Hz,3H).

[0141] Example 28 5-[(4R,8S,9aS)-8-[[6-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]oxy]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0142] The title compound was prepared similarly to that of Example 11 by using 2-chloro-5-hydroxypyridine (CAS: 41288-96-4) and tert-butyl ((3R,4S)-4-methoxypyrrolidin-3-yl)carbamate (CAS: 1932508-77-4, PharmaBlock) instead of 5-chloropyridin-2-ol (compound 11b) and tert-butyl piperazine-1-carboxylate (compound 11d). Example 28 (6 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 514 (MH + ), measured value 514(MH + ). 1H NMR(400MHz, methanol-d4)δ 8.88(dd,J=4.2,1.3Hz,1H), 8.57(dd,J=8.5,1.3Hz,1H), 8.06(d,J=7.9Hz,1H), 7.84(dd,J=9.7,2.7Hz,1H), 7.79(d, J=2.7Hz,1H), 7.57(dd,J=8.6,4.2Hz,1H), 7.24(d,J=7.9Hz,1H), 6.99(d,J=9.7Hz,1H), 4.76-4.72(m,1H), 4.27-4.20 (m,1H), 4.09-3.98(m,2H), 3.96-3.89(m,1H), 3.88-3.74(m,3H), 3.71-3.56(m,3H), 3.55-3.49(m,1H), 3.40(s,3H), 3.36-3.26(m,1H), 3.19-3.05(m,2H), 2.31-2.22(m,2H), 2.20-2.06(m,1H), 2.05-1.94(m,1H), 1.41(d,J=6.5Hz,3H).

[0143] Example 29 5-[(4R,8S,9aS)-4-Methyl-8-[(5-piperazin-1-yl-3-pyridyl)oxy]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0144] The title compound was prepared similarly to the preparation of Example 11 by using 3-bromo-5-hydroxypyridine (CAS: 74115-13-2) instead of 5-chloropyridin-2-ol (compound 11b). Example 29 (3 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 484 (MH + ), measured value 484(MH + ). 1H NMR (400MHz, methanol-d4) δ 9.02(dd,J=1.6,4.3Hz,1H), 8.70(dd,J=1.6,8.6Hz,1H), 8.21(d,J=7.9Hz,1H), 8.13(br d,J=19.7Hz,2H), 7.69(dd,1H,J=4.3,8.6Hz), 7.61(s,1H), 7.38(d,J=7.9Hz,1H), 5.14(br s,1H), 4.16(br t,J=11.6Hz,1H), 3.9-4.0(m,2H), 3.7-3.8(m,1H), 3.6-3.7(m,5H), 3.4-3.5(m,5H), 3. 2-3.3(m,2H), 2.4-2.5(m,2H), 2.2-2.4(m,1H), 2.1-2.2(m,1H), 1.53(d,J=6.5Hz,3H).

[0145] Example 30 5-[(4R,8R,9aS)-8-[3-[4-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]phenyl]azetidin-1-yl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0146] The title compound was prepared similarly to the preparation of Example 9 by using tert-butyl ((3R,4R)-4-methoxypyrrolidin-3-yl)carbamate (CAS: 1932066-52-8, PharmaBlock) instead of tert-butyl piperazine-1-carboxylate (compound 9c). Example 30 (4 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 552 (MH + ), measured value 552(MH + ). 1H NMR(400MHz, methanol-d4)δ 8.87(dd,J=4.3,1.6Hz,1H), 8.51(dd,J=8.6,1.6Hz,1H), 8.04(d,J=8.1Hz,1H), 7.53(dd,J=8.6,4.2Hz,1H), 7.01-7.18(m,3H), 6. 49(m,2H), 3.70-3.98(m,3H), 3.41-3.66(m,4H), 2.99-3.16(m,11H), 2.37-2.81(m,5H), 1.71-2.04(m,3H), 0.90-1.38ppm(m,4H).

[0147] Example 32 5-[(4R,8R,9aS)-8-[3-[4-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]phenyl]azetidin-1-yl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile [ka]

[0148] The title compound was prepared similarly to the preparation of Example 9 by using tert-butyl ((3R,4S)-4-methoxypyrrolidin-3-yl)carbamate instead of tert-butyl piperazine-1-carboxylate (compound 9c). The stereochemistry was confirmed by NOESY. Example 32 (2 mg) was obtained as a pale yellow solid. MS: calculated 552 (MH + ), measured value 552(MH + ). 1H NMR(400MHz, methanol-d4)δ 9.04(dd,J=4.2, 1.5Hz,1H), 8.67(dd,J=8.6,1.7Hz,1H), 8.22(d,J=7.9Hz,1H), 7 .70(dd,J=8.6,4.3Hz,1H), 7.34(dd,J=19.0,8.4Hz,3H), 6.68(d,J=8.7Hz,2H), 4. 46-4.66(m,2H), 4.20-4.39(m,3H), 3.94-4.17(m,3H), 3.40-3.83(m,10H), 3.05-3 .25(m,3H), 2.78-3.01(m,2H), 2.33-2.53(m,2H), 1.59-1.99(m,2H), 1.46(s,3H).

[0149] Example 34 5-[(4R,8R,9aS)-4-Methyl-8-[4-[[(2S)-morpholin-2-yl]methyl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile [ka]

[0150] The title compound was prepared similarly to the preparation of Example 1 by using tert-butyl (S)-2-(4-aminobenzyl)morpholine-4-carboxylate and 2-deuterio-5-[(4R)-4-methyl-8-oxo-3,4,6,7,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate D1) instead of tert-butyl 4-(4(aminomethyl)phenyl)piperazine-1-carboxylate (Compound 1a) and 5-((4R,9aS)-4-methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Intermediate C1). Example 34 (34 mg) was obtained as a pale yellow solid. The stereochemistry was confirmed by NOESY. MS: calculated 498 (MH + ), measured value 498(MH + ). 1H NMR(400MHz, methanol-d4)δ 8.58(d,J=8.6Hz,1H), 8.08(d,J=7.9Hz,1H), 7.59(d,J=8.6Hz,1H), 7.25(d,J =7.9Hz,1H), 6.92(d,J=8.6Hz,2H), 6.58(d,J=8.6Hz,2H), 3.98-3.89(m,2H), 3.82-3.50(m,7H), 3.15-2.95(m,6H), 2.78-2.64(m,2H), 2.59-2.51(m,1H), 2 .36-2.23(m,2H), 1.72-1.59(m,1H), 1.50-1.41(m,1H), 1.39(d,J=6.4Hz,3H).

[0151] Example 36 5-[(4R,8R,9aS)-8-[3-[4-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]phenyl]azetidin-1-yl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]]-2-deuterio-quinoline-8-carbonitrile [ka]

[0152] The title compound was prepared in a similar manner to the preparation of Example 9 by using 2-deuterio-5-[(4R)-4-methyl-8-oxo-3,4,6,7,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate D1) and tert-butyl N-[(3R,4S)-4-methoxypyrrolidin-3-yl]carbamate (CAS: 1932508-77-4, PharmaBlock) instead of 5-((4R,9aS)-4-methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Intermediate C1) and tert-butyl piperazine-1-carboxylate (Compound 9c). Example 36 (7 mg) was obtained as a pale yellow solid. MS: Calculated value 553 (MH + ), measured value 553(MH + ). 1H NMR(400MHz, methanol-d4)δ 8.56(d,J=8.7Hz,1H), 8.10(d,J=7.9Hz,1H), 7.59(d,J=8.6Hz,1H), 7.23(dd,J=18.5,8.3Hz,3H), 6.61(d,J=8.8Hz,2H), 4.48-4.38(m,2H), 4.25-4.14(m,2H), 4.04-3.94(m,3H), 3.82-3.73(m,2H) , 3.70-3.63(m,1H), 3.62-3.52(m,5H), 3.38-3.36(m,3H), 3.35-3.31(m,1H), 3.18-3.01(m,3H), 2 .95-2.84(m,1H), 2.40-2.27(m,2H), 1.84-1.72(m,1H), 1.67-1.56(m,1H), 1.36(d,J=6.2Hz,3H).

[0153] Example 37 5-[(4R,8R,9aS)-4-Methyl-8-[4-(4-pyridyl)piperazin-1-yl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile [ka]

[0154] The title compound was prepared similarly to the preparation of Example 1 by using 1-(pyridin-4-yl)piperazine and 2-deuterio-5-[(4R)-4-methyl-8-oxo-3,4,6,7,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate D1) instead of tert-butyl 4-(4-(aminomethyl)phenyl)piperazine-1-carboxylate (Compound 1a) and 5-((4R,9aS)-4-methyl-8-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (Intermediate C1) in step 1. Example 37 (3 mg) was obtained as a pale yellow solid. MS: calculated 469 (MH + ), measured value 469(MH + ). 1H NMR(400MHz, methanol-d4)δ 8.52(d,J=8.6Hz,1H), 7.96-8.11(m,3H), 7.53(d,J=8.7Hz,1H), 7.13(d,J=8.1Hz,1H), 6.66-6.83(m,2H), 3.26- 3.45(m,9H), 2.51-2.80(m,7H), 1.74-2.04(m,3H), 1.43-1.62(m,1H), 1.18-1.35(m,1H), 1.09(d,J=6.2Hz,3H).

[0155] Example 38 The following studies were performed to determine the activity of compounds of formula (I) and formula (Ia) in the HEK293-Blue-hTLR-7 / 8 / 9 cell assay.

[0156] HEK293-Blue-hTLR-7 Cell Assay: A stable HEK293-Blue-hTLR-7 cell line was purchased from InvivoGen (catalog #: hkb-htlr7, San Diego, CA, USA). These cells were originally designed to study the stimulation of human TLR7 by monitoring the activation of NF-κB. The SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of an IFN-β minimal promoter fused to five NF-κB and AP-1 binding sites. SEAP was induced by activating NF-κB and AP-1 via stimulating HEK-Blue hTLR7 cells with TLR7 ligands. Thus, reporter expression was reduced by TLR7 antagonists under the stimulation of ligands such as R848 (Resiquimod) for 20 h of incubation. The activity of the SEAP reporter in cell culture supernatants was measured using QUANTI-Blu TM The detection medium turned purple or blue in the presence of alkaline phosphatase, measured at a wavelength of 640 nm using a kit (catalog #: rep-qb1, Invivogen, San Diego, CA, USA).

[0157] HEK293-Blue-hTLR7 cells were incubated in a 96-well plate at a density of 250,000 to 450,000 cells / mL in 170 μL of Dulbecco's modified Eagle medium (DMEM) (containing 4.5 g / L glucose, 50 U / mL penicillin, 50 mg / mL streptomycin, 100 mg / mL normocin, 2 mM L-glutamine, and 10% (v / v) heat-inactivated fetal bovine serum) with serially diluted 20 μL of test compound, in the presence of 1% final DMSO and 10 μL of 20 uM R848 in the above DMEM, and incubated at 37°C in a CO2 incubator for 20 hours. Then, 20 μL of supernatant from each well was incubated with 180 μL of Quanti-blue substrate solution for 2 h at 37°C, and the absorbance was read at 620-655 nm using a spectrophotometer. The signaling pathway in which TLR7 activation leads to downstream NF-κB activation has been widely accepted, and therefore, a similar reporter assay was modified to evaluate TLR7 antagonists.

[0158] HEK293-Blue-hTLR-8 Cell Assay: A stable HEK293-Blue-hTLR-8 cell line was purchased from InvivoGen (catalog #: hkb-htlr8, San Diego, CA, USA). These cells were originally designed to study the stimulation of human TLR8 by monitoring the activation of NF-κB. A SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of an IFN-β minimal promoter fused to five NF-κB and AP-1 binding sites. SEAP was induced by activating NF-κB and AP-1 via stimulating HEK-Blue hTLR8 cells with TLR8 ligands. Thus, reporter expression was reduced by TLR8 antagonists under the stimulation of ligands such as R848 for 20 h of incubation. The activity of the SEAP reporter in cell culture supernatants was measured using QUANTI-Blu TMThe detection medium turned purple or blue in the presence of alkaline phosphatase, measured at a wavelength of 640 nm using a kit (catalog #: rep-qb1, Invivogen, San Diego, CA, USA).

[0159] HEK293-Blue-hTLR8 cells were incubated in a 96-well plate at a density of 250,000 to 450,000 cells / mL in 170 μL of Dulbecco's modified Eagle medium (DMEM) (containing 4.5 g / L glucose, 50 U / mL penicillin, 50 mg / mL streptomycin, 100 mg / mL normocin, 2 mM L-glutamine, and 10% (v / v) heat-inactivated fetal bovine serum) with 20 μL of serially diluted test compounds, in the presence of 1% final DMSO and 10 μL of 60 uM R848 in the above DMEM, and incubated at 37°C in a CO2 incubator for 20 hours. Then, 20 μL of supernatant from each well was incubated with 180 μL of Quanti-blue substrate solution for 2 h at 37°C, and the absorbance was read at 620-655 nm using a spectrophotometer. The signaling pathway in which TLR8 activation leads to downstream NF-κB activation has been widely accepted, and therefore, a similar reporter assay was modified to evaluate TLR8 antagonists.

[0160] HEK293-Blue-hTLR-9 Cell Assay: A stable HEK293-Blue-hTLR-9 cell line was purchased from InvivoGen (catalog #: hkb-htlr9, San Diego, CA, USA). These cells were originally designed to study the stimulation of human TLR9 by monitoring the activation of NF-κB. The SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of an IFN-β minimal promoter fused to five NF-κB and AP-1 binding sites. SEAP was induced by activating NF-κB and AP-1 via stimulating HEK-Blue hTLR9 cells with TLR9 ligands. Thus, reporter expression was reduced by TLR9 antagonists under the stimulation of ligands such as ODN2006 (catalog #: tlrl-2006-1, Invivogen, San Diego, CA, USA) for 20 h of incubation. The activity of the SEAP reporter in the cell culture supernatant was measured using QUANTI-Blue TM The detection medium turned purple or blue in the presence of alkaline phosphatase, measured at a wavelength of 640 nm using a kit (catalog #: rep-qb1, Invivogen, San Diego, CA, USA).

[0161] HEK293-Blue-hTLR9 cells were incubated at a density of 250,000-450,000 cells / mL in a volume of 170 μL in a 96-well plate in Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 g / L glucose, 50 U / mL penicillin, 50 mg / mL streptomycin, 100 mg / mL normocin, 2 mM L-glutamine, 10% (v / v) heat-inactivated fetal bovine serum, 20 μL of test compound serially diluted in the presence of 1% final DMSO and 10 μL of 20 μM ODN2006 in the above DMEM, and incubated at 37°C for 20 hours in a CO2 incubator. Then, 20 μL of supernatant from each well was incubated with 180 μL of Quanti-blue substrate solution for 2 h at 37°C, and the absorbance was read at 620-655 nm using a spectrophotometer. The signaling pathway in which TLR9 activation leads to downstream NF-κB activation has been widely accepted, and therefore, a similar reporter assay was modified to evaluate TLR9 antagonists.

[0162] The compounds of formula (I) have human TLR7 and / or TLR8 inhibitory activity (IC 50 In addition, some compounds also have human TLR9 inhibitory activity of less than 0.5 μM. Activity data of the compounds of the present invention are shown in Table 2.

[0163] [Table 2]

[0164] Example 39 hERG Channel Inhibition Assay: The hERG channel inhibition assay is a highly sensitive measure to identify compounds that exhibit hERG inhibition associated with cardiotoxicity in vivo. + The channel has been cloned in human and stably expressed in a CHO (Chinese Hamster Ovary) cell line. hERGThe cells were used for patch clamp (voltage clamp, whole cell) experiments. The cells were stimulated with a voltage pattern to activate the hERG channel and induce I KhERG After the cells were allowed to stabilize for several minutes, I KhERG The amplitude and kinetics of I was recorded at a stimulation frequency of 0.1 Hz (6 bpm). Increasing concentrations of test compound were then added to the preparation. For each concentration, an attempt was made to reach a steady-state effect, which was usually achieved within 3-10 min, at which point the next higher concentration was applied. KhERG The amplitude and kinetics of the responses were recorded at each drug concentration and compared to control values ​​(set at 100%). (Reference: Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG.2003;Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.Cardiovasc.Res.58:32-45,Sanguinetti MC,Tristani-Firouzi M.2006;hERG potassium channels and cardiac arrhythmia.Nature 440:463-469,Webster R,Leishman D,Walker D.2002;Towards a drug concentration effect relationship for QT prolongation and torsades de pointes.Curr.Opin.Drug Discov. Dev. 5:116-26).

[0165] The results for hERG are shown in Table 3. The safety ratio (hERG IC 20 / EC 50 ) suggest a sufficient window to discern pharmacology by inhibiting the TLR7 / 8 / 9 pathway from potential hERG-related cardiac toxicity. The following hERG IC, which serves as an early selectivity index to assess hERG liability, 20 / TLR7 / 8 / 9 IC 50 According to the calculations of 、 Specifically, the reference compounds ER-887258, ER-888285, ER-888286, R1, and R2 have a very narrow safety window compared to the compounds of the present invention.

[0166] [Table 3]

[0167] Example 40 It would be desirable for the compound to have minimal liability to DDIs. Thus, the effect of the compound of formula (I) (Ia) on the major CYP isoforms, such as CYP2C9, CYP2D6 and CYP3A4, is determined.

[0168] CYP inhibition assay This is a high-throughput screening assay used to evaluate test compounds for reversible inhibition of CYP2C9, CYP2D6, and CYP3A4 activity in human liver microsomes (HLM) in the early discovery phase.

[0169] [Table 4]

[0170] procedure 10 mM DMSO stock solutions of test compounds were diluted in DMSO to yield 2 mM intermediate stock solutions. 250 nL of intermediate stock solutions were transferred in duplicate to three separate 384-well microtiter plates (Assay-Ready-Use Plates). A mixture of HLM and each substrate was prepared. 45 μL of HLM substrate mix was then transferred to each well of the Assay-Ready-Use Plates and mixed. Negative (solvent) and positive controls (standard inhibitors for each CYP) were included in each Assay-Ready-Use Plate. The Assay-Ready-Use Plates were warmed to 37° C. in an incubator for 10 minutes. 5 μL of pre-warmed NADPH regenerating system was added to each incubation well to initiate the reaction. The final incubation volume was 50 μL. The assay plates were then placed back into the 37° C. incubator. After 5 min of incubation (10 min for CYP2D6), the incubation was quenched by adding 50 μL of 100% acetonitrile containing internal standards (400 ng / mL 13C6-4'-OH-diclofenac, 20 ng / mL D3-dextrorphan, 20 ng / mL D4-1'OH-midazolam) and the supernatant was collected for RapidFire / MS / MS analysis.

[0171] A RapidFire online solid phase extraction / sample injection system (Agilent) coupled with an API4000 triple quadrupole mass spectrometer (AB Sciex) was used for sample analysis. The mobile phase consisted of acetonitrile and water supplemented with 0.1% formic acid. C4 solid phase extraction cartridges are used for sample separation. MS detection is achieved in positive ion MRM mode.

[0172] Data analysis The peak areas for the substrate, metabolites and internal standards were measured using the RapidFire integration software (version 3.6.12009.12296). The peak area ratios (PAR) of the metabolites and internal standards (stable labeled metabolites) were then calculated. A measurement window for each experiment was then defined: PAR(0% activity)=average PAR for all incubations containing concentrated inhibitor; Par (100% activity) = average PAR for all incubations containing no inhibitor (DMSO control); % Activity (Test Inhibitor) = [PAR(test inhibitor)-PAR(0% activity) / [PAR(100% activity)-PAR(0% activity)], % Inhibition(Test Inhibitor)=100-% Activity(Test Inhibitor).

[0173] The compounds of the present invention were found to have low CYP inhibition for CYP2D6 as determined in the assay described above.

[0174] [Table 5]

Claims

1. Formula (I) 【Chemistry 1】 (In the formula, R １ teeth, 【Chemistry 2】 where R ４ is C １－６ Alkyl, C １－６ Alkoxy, HaloC １－６ alkyl, halogen, nitro or cyano; R ４ａ is C １－６ Alkyl or C ３－７ is cycloalkyl; R ５ , R ５ａ and R ５ｂ is independently selected from H and deuterium; R ６ is H or a halogen; R ２ is C １－６ is alkyl; R ３ is ((amino (C １－６ alkoxy)pyrrolidinyl)phenyl)azetidinyl, (amino(C １－６ alkoxy)pyrrolidinyl)pyridinyl, (amino(C １－６ (alkoxy)pyrrolidinyl)pyridinyloxy, (amino-1,4-oxazepanyl)pyridinyl, (aminoazetidinyl)pyridinyl, (morpholinyl C １－６ alkyl)phenyl, (morpholinyl C １－６ (alkyl)phenylamino, (piperazinylphenyl)azetidinyl, (piperazinylphenyl)C １－６ alkylamino, aminohalopyrrolidinyl, morpholinylphenyl, morpholinylphenylamino, piperazinylphenyl, piperazinylpyridinyl, piperazinylpyridinyloxy, piperazinylpyrimidinyloxy or pyridinylpiperazinyl). or a pharma- ceutically acceptable salt thereof.

2. R １ but, 【Chemistry 3】 where R ４ is cyano; R ５ The compound of claim 1 , wherein is H or deuterium.

3. R ３ but ((3-amino-4-methoxy-pyrrolidin-1-yl)phenyl)azetidin-1-yl; (3-amino-4-methoxy-pyrrolidin-1-yl)-3-pyridinyl; (3-amino-4-methoxy-pyrrolidin-1-yl)-3-pyridinyloxy; (3-aminoazetidin-1-yl)-3-pyridinyl; (4-morpholin-2-ylmethyl)phenyl; (4-morpholin-2-ylmethyl)phenylamino; (4-piperazin-1-ylphenyl)azetidin-1-yl; (4-piperazin-1-ylphenyl)methylamino; (6-amino-1,4-oxazepan-4-yl)-3-pyridinyl; 2-Piperazin-1-ylpyrimidin-5-yloxy; 3-Amino-4-fluoro-pyrrolidin-1-yl; 4-morpholin-2-ylphenyl; 4-morpholin-2-ylphenylamino; 4-Piperazin-1-ylphenyl; 4-Pyridinylpiperazin-1-yl; The compound of claim 2 which is 5-piperazin-1-yl-2-pyridinyloxy; 5-piperazin-1-yl-3-pyridinyloxy; 6-piperazin-1-yl-3-pyridinyl or 6-piperazin-1-yl-3-pyridinyloxy.

4. R ２ The compound according to any one of claims 1 to 3, wherein is methyl.

5. R ３ However, (morpholinyl C １－６ 3. The compound of claim 2 which is (alkyl)phenylamino, (piperazinylphenyl)azetidinyl, morpholinylphenyl, morpholinylphenylamino, piperazinylpyridinyloxy or piperazinylpyrimidinyloxy.

6. R ３ is (4-morpholin-2-ylmethyl)phenylamino, (4-piperazin-1-ylphenyl)azetidin-1-yl, 4-morpholin-2-ylphenyl, 4-morpholin-2-ylphenylamino, 6-piperazin-1-yl-3-pyridinyloxy or 2-piperazin-1-ylpyrimidin-5-yloxy.

7. R １ but, 【Chemistry 4】 where R ４ is cyano; R ５ is H or deuterium; R ２ But, C １－６ is alkyl; R ３ However, (morpholinyl C １－６ (alkyl)phenylamino, (piperazinylphenyl)azetidinyl, morpholinylphenyl, morpholinylphenylamino, piperazinylpyridinyloxy or piperazinylpyrimidinyloxy; 6. The compound of claim 5, or a pharma- ceutically acceptable salt thereof.

8. R １ but, 【Chemistry 5】 where R ４ is cyano; R ５ is H or deuterium; R ２ is methyl, R ３ is (4-morpholin-2-ylmethyl)phenylamino, (4-piperazin-1-ylphenyl)azetidin-1-yl, 4-morpholin-2-ylphenyl, 4-morpholin-2-ylphenylamino, 6-piperazin-1-yl-3-pyridinyloxy or 2-piperazin-1-ylpyrimidin-5-yloxy; 8. The compound of claim 7, or a pharma- ceutically acceptable salt thereof.

9. 5-[(4R,8R,9aS)-4-methyl-8-[(4-piperazin-1-ylphenyl)methylamino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-[(4-piperazin-1-ylphenyl)methylamino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R)-4-methyl-8-(6-piperazin-1-yl-3-pyridyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R)-4-methyl-8-(4-piperazin-1-ylphenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-(6-piperazin-1-yl-3-pyridyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-[(3S,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-(3-aminoazetidin-1-yl)-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-[3-(4-piperazin-1-ylphenyl)azetidin-1-yl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-[(5-piperazin-1-yl-2-pyridyl)oxy]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-[(3S,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aR)-4-methyl-8-(6-piperazin-1-yl-3-pyridyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-[(6-piperazin-1-yl-3-pyridyl)oxy]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-(2-piperazin-1-ylpyrimidin-5-yl)oxy-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[6-[(3R,4S)-3-amino-4-fluoro-pyrrolidin-1-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-[4-[(2S)-morpholin-2-yl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-[4-[[(2R)-morpholin-2-yl]methyl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-Methyl-8-[4-[[(2R)-morpholin-2-yl]methyl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile 5-[(4R,8R,9aS)-8-[6-[(6S)-6-amino-1,4-oxazepan-4-yl]-3-pyridyl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-(4-morpholin-2-ylphenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-[4-[(2R)-morpholin-2-yl]phenyl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-[4-[[(2R)-morpholin-2-yl]methyl]phenyl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-[4-(morpholin-2-ylmethyl)phenyl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-8-[[6-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]-3-pyridyl]oxy]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8S,9aS)-4-methyl-8-[(5-piperazin-1-yl-3-pyridyl)oxy]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[3-[4-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]phenyl]azetidin-1-yl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[3-[4-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]phenyl]azetidin-1-yl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-4-methyl-8-[4-[[(2S)-morpholin-2-yl]methyl]anilino]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile; 5-[(4R,8R,9aS)-8-[3-[4-[(3R,4S)-3-amino-4-methoxy-pyrrolidin-1-yl]phenyl]azetidin-1-yl]-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]]-2-deuterio-quinoline-8-carbonitrile; and 5-[(4R,8R,9aS)-4-methyl-8-[4-(4-pyridyl)piperazin-1-yl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile; or a pharma- ceutically acceptable salt thereof.

10. The following step a): a) a compound of formula (VIII) 【Chemistry 6】 and an amine (V) 【Chemistry 7】 Buchwald-Hartwig amination reaction between wherein X is a halogen; R ７ is H; R ８ Heterocyclylheteroaryl, heterocyclylC １－６ Alkylheteroaryl, heterocyclylheteroaryl C １－６ Alkyl, Heterocyclyl C １－６ Alkylaryl, heterocyclylaryl C １－６ alkyl; or R ７ and R ８ together with the nitrogen to which they are attached form a heterocyclyl; R １ and R ２ is as defined in any one of claims 1 to 8. A method for producing the compound according to any one of claims 1 to 9, comprising:

11. The following step b): b) Amines (V) 【Chemistry 8】 Compound of formula (IV) 【Chemistry 9】 Reductive amination of wherein R 7 is H; R 8 is heterocyclylheteroaryl, heterocyclylC 1-6 alkylheteroaryl, heterocyclylheteroarylC 1-6 alkyl, heterocyclylC 1-6 alkylaryl, heterocyclylarylC 1-6 alkyl; or R 7 and R 8 together with the nitrogen to which they are attached form a heterocyclyl; and R 1 and R 2 are as defined in any one of claims 1 to 8. A method for producing the compound according to any one of claims 1 to 9, comprising:

12. The process of claim 11, c) a compound of formula (XIV) 【Chemistry 10】 and an amine (V) 【Chemistry 11】 Buchwald-Hartwig amination reaction between wherein X is halogen; R 7 is H; R 8 is heterocyclylheteroaryl, heterocyclylC 1-6 alkylheteroaryl, heterocyclylheteroarylC 1-6 alkyl, heterocyclylC 1-6 alkylaryl, heterocyclylarylC 1-6 alkyl; or R 7 and R 8 together with the nitrogen to which they are attached form a heterocyclyl; W is heteroaryl or aryl; and R 1 and R 2 are as defined in any one of claims 1 to 8. A method for producing the compound according to any one of claims 1 to 9, comprising:

13. The following step d): d) A compound of formula (XVIII) 【Chemistry 12】 and an amine (V) 【Chemistry 13】 Buchwald-Hartwig amination reaction between wherein X is halogen; R 7 is H; R 8 is heterocyclylheteroaryl, heterocyclylC 1-6 alkylheteroaryl, heterocyclylheteroarylC 1-6 alkyl, heterocyclylC 1-6 alkylaryl, heterocyclylarylC 1-6 alkyl; or R 7 and R 8 together with the nitrogen to which they are attached form a heterocyclyl; W is heteroaryl or aryl; and R 1 and R 2 are as defined in any one of claims 1 to 8. A method for producing the compound according to any one of claims 1 to 9, comprising:

14. 10. A compound, or a pharma- ceutically acceptable salt, according to any one of claims 1 to 9 for use as a therapeutically active substance.

15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9 and a therapeutically inert carrier.

16. 16. The pharmaceutical composition according to claim 15 for the treatment or prevention of systemic lupus erythematosus or lupus nephritis.

17. Use of a compound according to any one of claims 1 to 9 for the preparation of a medicament for the treatment or prevention of systemic lupus erythematosus or lupus nephritis.

18. 16. The pharmaceutical composition of claim 15 for use as a TLR7 or TLR8 or TLR9 antagonist.

19. 10. Use of a compound according to any one of claims 1 to 9 for the preparation of a medicament for a TLR7 and TLR8 and TLR9 antagonist.

20. A compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt thereof, for the treatment or prevention of systemic lupus erythematosus or lupus nephritis.

Images